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CHAPTER 1 
INTRODUCTION 
1.1 GPCRs and GIRK Channels  
G-Protein Coupled Receptors (GPCRs) are a large family of receptors with numerous functions 
including regulating electrical excitability in cardiac and neuronal tissue1 by acting on ion 
channels. Excitability of nerves and muscles is guided by the membrane potential of cells, or the 
ability to move ions such as Na+, K+ or Cl- through ion channels. One of these ion channel families 
is the G Protein-gated Inwardly Rectifying Potassium (GIRK) channels, comprised of the Kir3.1-
3.4 (GIRK 1/2, 2/2, 2/3, 1/3 and 1/4)1. 
 
Figure 1.1. GIRK channels form GIRK2 stable homotetramer or heterotetramers GIRK1/2, GIRK1/4, GIRK1/3 
(not shown) and GIRK2/3 (not shown). 
 
 
Potassium channels cover a variety of functions such as setting the resting potential, 
terminate periods of intense activity and generally lower the effectiveness of excitatory inputs2. 
Specifically, GIRKs are expressed as homo and heterotetramers membrane spanning subunits3 that 
permit the outward flow of K+ ions (efflux) which creates an inhibitory effect, or 
hyperpolarization4. This outward ionic gradient is established by Na/K pumps which regulates the 
membrane potential. Occlusion of the central pore by intracellular Mg2+ or polyamines occurs at 
membrane potentials above the equilibrium potential of K+ (EK)
1.  
3 
2 
3 
2 
3 
2 
3 3 
4 
3 
1 1 
2 
  
Figure 1.2. Used with permission from Luscher1 and Whorton and McKinnin3. (Left) Current plotted as a function 
of voltage for GIRK channels. Red line (basal) current verses agonist induced current (blue) shows inward rectification 
(large inward current and small outward current). EK indicates equilibrium potential and blue shaded area shows the 
hyperpolarization of the cell membrane. High external K+ shifts the EK.  (Right)GIRK channels are typically activated 
by an agonist interacting with the GPCR. In the presence of PIP2, K+ effluxes to the extracellular. 
 
Functionally, when a neurotransmitter (e.g. acetylcholine in cardiac tissue) binds to the G protein-
coupled receptor and causes the release of the G subunits. These subunits activate the G protein-
gated Inward Rectifying potassium channel and causes them to open leading to a release of 
potassium (K+). Potassium ion release drives the cell membrane towards a resting potential and 
reduces excitability in the cell signaling3. In addition to cardiac tissue (GIRK 1/4), GIRK channels 
are also dispersed widely in the brain (GIRK 1/2, 2/2, 2/3, 1/3)5, and function in a similar way to 
control neuronal excitability3.  
 
Dysregulation of GIRK Channels  
Dysregulation of GIRK channels has been implicated in several disease states such as 
movement disorders6, schizophrenia7, drug addiction and withdrawals8, epilepsy9 and pain10 
(Figure 1.3). For example, Harkins and coworkers8, studied mice with the weaver mutation to 
better understand ataxia and Parkinson’s disease. Not only did these mice suffer from neurological 
3 
movement disorders, they also showed signs of degenerating dopaminergic neurons through a 
mutation that causes neurons to fail to differentiate and migrate. This mutation in GIRK2 channels 
(G156S) is an altered glycine found in all K+ channels, causing the loss of K+ selectivity and 
permitting Na+ and Ca2+ ions to permeate the cell which leads to cell death. As evidenced in the 
weaver mutation study, we have only recently begun to comprehend how important these channels 
are in normal and pathological central nervous system states. The development of small molecules 
that can act as selective molecular “switches” that controls activity at specific GIRK channels to 
first elucidate their role in normal physiology and then evaluate their potential to alleviate can offer 
us a way of treating or prevent these disorders.  
 
Figure 1.3. GIRK channels have been implicated in a number of disease states, diagram used with permission from 
Lüscher and Slesinger1.  
 
 
4 
X-ray structure of GIRK2 -  G protein complex 
Many electrophysiological and biochemical studies have been conducted to determine how 
GPCR subunit activate GIRK channels.  The crystal structure of a GIRK2 channel bound to the 
G subunits also shows the gating regulators of Na+ and PIP2 as illustrated in Figure 1.4.  
Figure 1.4. Used with permission from Whorton and MacKinnon3. (a) Side view of crystal structure of GIRK 
channel with G subunits bound to the channel. Front subunits have been removed for clarity. Note transmembrane 
channel with the turret extruding from the extracellular side. (b) Top view of crystal structure of GIRK channel with 
G subunits bound to the channel. Note K+ ion passing through the open channel. PIP2 is also required to be bound 
for GIRK channel activity.   
 
The authors show the GIRK channels to be modified by the G subunits and point out the 
importance of the G subunits such as how many are required for opening of the channel. They also 
indicate the importance of the presence of PIP2 and/or Na
+ which acts as a GIRK channel activator.  
The stoichiometry of GIRK channels to subunits, as shown, four G were found associated with 
the open conformation due to the stabilizing effect of opening the channel. This study provided an 
excellent look at how these transmembrane proteins activate but further studies are required to 
really examine the mechanism of GIRK channel activity.  
5 
1.2 Discovery of Small Molecule GIRK Channel Regulators using Metal Sensing Dyes  
Many currently marketed drugs act target GPCRs for example Atrovent, which targets 
muscarinic M1 and M2 receptors for chronic obstructive pulmonary disease11. Full reviews on this 
topic are widely available12.  As GPCRs regulate ion channels monitoring of ion channel activity 
serves as a common screening paradigm for the discovery of small molecules that regulate GPCR12 
activity as well as ion channel activity directly. One method of monitoring ion channel activity is 
the use of small molecule probes that change fluorescence upon specific ion binding. Metal 
detection can occur by either quenching or enhancing fluorescence. In the case of monitoring 
potassium ion channels, Hille originally determined that Tl+ was a size surrogate for K+ channels2  
and  Weaver13 determined upon binding to Thallos™ results in enhanced fluorescence presumably 
by photoinduced electron transfer (PET) (Figure 1.5).  
 
Figure 1.5.  Thallos™ is prepared as bisacetoxy fluorescein with N-(2-methoxyphenyl)iminodiacetate protected 
acetoxymethyl esters. Cellular esterases deprotect the metal sensor and based on internal pH, the phenol equilibrates 
to the active dye form. Photoinduced electron transfer (PET) from the amino quenches the fluorescence, as shown as 
electron density traveling up the “molecular wire” (red). Thallos™ in the presence of a metal ion, (Tl+) will dequench 
the fluorescein fluorophore and permit an increase in fluorescence. 
  
6 
Xanthene Based Fluorophores: Fluorescein and Rhodamine  
 The process of fluorescence is a molecule absorbing a photon from the ground (S0) to the 
excited singlet state (S1), as shown in the Jabloński diagram in Figure 1.6. Fluorescence results a 
release of a photon (λν) as the fluorophore returns to the ground S0 from the excited S114. 
Wavelength emission (ʎmax) is typically shifted red compared to the absorbance wavelength (ʎabs), 
is known as Stoke’s shift, due to interactions  
 
Figure 1.6. Taken from Lavis and coworkers14 i) A photon is being absorbed to give  the excited singlet state. ii) 
Conversion into the singlet state iii) Fluorescence is the relaxation (release of light) of the singlet into the ground state. 
iv) Describes non-radiative decay (loss as heat) and v) Förster resonance energy transfer vi) Intersystem crossing to 
triplet state (T1) vii) Phosphorescence and viii) non-radiative decay.  
 
of the excited molecule with surrounding solvent reorganization. Absorption of the molecule is 
based on the ʎabs and the extinction coefficient (ɛ), which is defined by how strongly a molecule 
can absorb light. Quantum yield (ɸ) is a ratio of photons going into the molecule over photons 
leaving. For example, fluorescein, a xanthene based fluorophore, has an efficient quantum yield 
(ɸ = 0.86, ideally 1.00), typically absorbs blue light (490 nm) and emits green light (510 nm)14 
with an extinction coefficient of 9.0 × 104 M−1 cm−1. These properties are a part of many 
7 
contributing factors that makes xanthene fluorophores one of the most widely utilized fluorophore 
in research.  
 
Photoinduced Electron Transfer  
 Fluorescence properties of a fluorophore can be modulated by the metal and the fluorophore, 
known as photoinduced electron transfer (PET)7. In the absence of a metal ion, a separation of 
charge forms on the excited fluorophore and this competes with fluorescence emission. PET then 
gives rise to a more efficient relaxation pathway (S1 to S0, energy loss through non-radiative decay) 
than fluorescence and decreases the optical output of the fluorophore. When a metal ion is bound, 
this disrupts the PET relaxation pathway and increases the quantum yield (Figure 1.7). This tuning 
of electron density with the choice of fluorophore, linker (molecular wire) and the metal binder 
can be achieved with electron withdrawing and donating groups that alter the efficiency of the PET 
 
Figure 1.7.  (Left) In the absence of a metal, PET offers a more efficient relaxation pathway and decreases the 
optical output of the fluorophore. (Middle) When chelated to a metal ion, the PET effect is disrupted and increases the 
quantum yield. (Right) Schematic of a metal sensor with a (I) Fluorophore, (II) molecular wire and (III) metal binding 
unit. Modification of these three parts can tune the PET effect adventitiously.  
 
quenching effect. The depth of small molecule dyes for fluorescence assay is very broad and there 
are several excellent reviews and resources on the subject15. The focus of this dissertation work is 
8 
primarily xanthene scaffolds, which hold a unique open-close like switch to the fluorescence. 
Fluorescein and rhodamine both share a common spirocyclic core scaffold, xanthene, which 
undergoes an open (fluorescent, quinoid or aza-quinoid) close (non-fluorescent, spiro-lactone) 
equilibrium. This equilibrium is dependent on pKa16 by introducing an electron withdrawing group 
adjacent to the aniline or phenol (e.g. F, Cl, etc). This equilibrium can also be controlled by 
“protecting”, or by alkylating (ether, amino) or acetylating (ester, amide), which forces the 
xanthene into the closed, non-fluorescent form (Figure 1.8). A large number of fluorescent dyes 
have been prepared in this protected or masked manner with various trigger groups such as photo-
activating releasing groups17, enzyme selective cleavage18 and small-molecule sensors19.  
 
Figure 1.8. Xanthene fluorophore scaffold in equilibrium between closed-lactone (off) and open quinoid (on). 
Dianion species reported as the most fluorogenic16. 
 
Dye properties have been exploited based on pKa of the functional groups, for example, 
rhodamine which carries a positive charge (at pH<6.0) when localized in the mitochondrion20. In 
this manner, rhodamine may be used as a dye that is specific for tracking membrane potential in 
mitochondria. Rhodamine will accumulate in the mitochondria due to its positive charge at cellular 
pH and this high concentration will cause a self-quenching (or decrease in fluorescent signal). 
When the membrane potential is disrupted, rhodamine will then exit the mitochondria and the 
9 
increase in fluorescence is detected. Traditionally, the synthesis of xanthene scaffolds consisted of 
heating of phthalic anhydride with resorcinol under strong acidic conditions (typically 
condensation with CH3SO3H)
21. The addition of any functionality to the phenol or anhydride 
would result in a mixture of isomers that would require careful conditions to separate22. Ways 
around this issue have been proposed synthetically, including Pd cross-coupling chemistry with 
Buchwald-Hartwig23 by conversation of an aryl triflate into an aniline. Despite the recent advances 
in dye chemistry, the coupling of functionality (metal sensor, protein tag) to the fluorescent 
molecule can prove to be synthetically challenging.  
  
10 
Table 1.1. Commonly Used Xanthene Based Dyes Structures and Properties15  
Structure Name abs 
(nm)  
ems 
(nm) 
ɸ (M−1cm−1) Usage 
 
Fluorescein  490 510 0.92 9.0X104 Microscopy 
Industrial 
Applications 
 
Rhodamine 
110 
496 520 0.86 8.3X104 Microscopy 
Spectroscopy 
 
Rhodamine 
123 
507 529 0.90 7.5 X104 Labeling 
mitochondria 
 
Tetramethyl 
rhodamine 
ethyl ester 
perchlorate 
(TMRE) 
549 574 NA 10.9X104 Mitochondria 
 
11 
 
Development and Use of Thallium Flux Assay 
 The work of the late Roger Tsein pioneered cell permeating fluorescent dyes24 that chelate 
mono- or divalent cations such as Ca2+. Before the development of the Thallium (Tl+) flux assay, 
measuring the activity of K+ was traditionally done with electrophysiology, rubidium (Rb+) flux 
assays or voltage sensitive dyes that measure the change in membrane potential13. The utility of 
fluorescent dyes as indicators for activity was attractive but the only dye at the time that directly 
bound potassium was benzofuran isophthalate (PBFI)25, which was not amendable to the screening 
of large libraries in a high-throughput manner due to their overlap in excitation (near UV) with 
many small molecule scaffolds. Similar to Rb+, Tl+ is a monovalent cation that is also permeable 
to potassium channels26. The use of Tl+ as a size surrogate for K+ channels was promising but the 
low solubility of Tl+ ions in assay buffer (TiCl in water, 5mM) required the exclusion of chloride 
ion to prevent salt precipitation.  
 
Figure 1.9.  GIRK channels permit the influx of Tl+ ions when activated by a compound. Thallos™  dye is incubated 
in the cells and dequenched (more fluorescent) in the presence of Tl+. Plot shows raw traces of increasing fluorescence 
over time in concentration response curves (CRC) 
12 
A common metal sensing dye utilized the benzothiazolylcoumarin (BTC) scaffold was found to 
detect Tl+ ions. The use of FluoZin, originally a Zn2+ dye, presented dequenching metal sensing 
upon the addition of Tl+ with the N-(2-methoxyphenyl)iminodiacetate chelation subunit (Figure 
1.6). The addition of Tl+ dequenched the fluoresence and presented a brighter form of the dye. 
Following this work, many authors reported the dye trapping properties of the cellular uptake and 
removal of the esterase sensitive acetoxymethyl (AM) ester pendant groups5. 
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Figure 1.10. N-(2-methoxyphenyl)iminodiacetate chelation subunit based off of BAPTA Ca2+ and Zn2+ sensors. 
Cellular esterases remove acetoxymethyl (AM) esters to reveal di-carboxylate, which is considered to contribute to a 
PET dequenching effect.   
 
 The requirement of a metal sensor that was more sensitive to concentrations of Tl+ drove 
towards the development of Thallos™, a BAPTA-AM hybrid linked to a xanthene fluorophore. 
While high-throughput screening of potassium channel activity has certainly benefited from Tl+ 
sensitive dyes, there are drawbacks, such as the need higher Tl+ affinity dyes or a way of detecting 
localized flux changes. 
 
Thallos™ Dye and Synthesis  
 Based on xanthene scaffolds, a large number of fluorescein based dyes have been 
functionalized for specific tasks, for example, a Tl+ sensing chelation moiety. Tl+ sensing dyes are 
based on a diacetate fluorescein scaffold with a metal chelation moiety attached through an amide 
bond. These dyes must diffuse as esters through the cellular membrane of cells expressing GIRK 
channels, release under the action of endogenous lipases and fluoresce with influx of Tl+ ions that 
bind to the metal sensing carboxylate group. The synthesis of Thallos™  starts with commercially 
available o-methoxy aniline and under basic conditions, alkylate with methyl bromoacetate build 
the acetoxymethyl (AM) ester chelation unit. Nitration proceeds smoothly to the para position and 
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then treatment with strong base gives the bis-acid. Alkylation with bromomethyl acetate prepares 
the AM esters and a clean reduction with Pd/C reveals the aniline. HATU coupling with bis-
acetylated mixture of 5- and 6-carboxyfluorescein gives Thallos™ at comparable yields.  
 
Scheme 1.1. Synthesis of Fluorescein-based Thallos™ with Metal Chelating Unit (Special thanks to Dr. Kwangho 
Kim). 
 
 
1.3 Prior Small Molecule GIRK Activators (or Inhibitors)  
 As discussed in the introduction GIRK channels have been implicated as therapeutic targets 
but largely remain unvalidated due to a lack of selective and potent small molecule modulators.  
Before the work of Lindsley and Weaver, there were few GIRK modulators that had potency below 
the micromolar range and were selective for GIRK channels. One example, NIP-142, a 
benzopyrane was found to inhibit atrial GIRK but also inhibited other cardiac potassium 
channels27.   
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Development of the Selective and Potent GIRK Activator, ML297  
 The discovery of small molecules that selectively activate and inhibit GIRK channels is 
essential for assessing their potential as therapeutic targets. In addition, development of molecules 
that are selective for neuronal GIRK1/2 channels may limit side effects caused by the activation 
of GIRK 1/4 in cardiac tissue. Prior to the work of Weaver, Lindsley, and others, there was a 
current lack of selective and potent small molecule activators except for Narigin, a known GIRK 
activator (>100 μM) and ethanol, found to be an activator (EC50 > 100 mM), but with poor 
selectivity and low potency28. During the course of screening for mGlu8 small molecule 
modulators, Weaver, Lindsley and coworkers identified small molecules that modulate GIRK 
channels directly. Lead optimization resulted in the GIRK1/2 and GIRK1/4 activator urea 1 
VU0456810 (ML297)9.  
 
Figure 1.11. Functionalization around initial GIRK channel hit VU0032230. ML297 SAR focused primarily around 
the “western” aryl and the requirement for an amide or urea linker. Later, probes were synthesized to better understand 
the importance of the eastern phenyl and heterocycle substitution off of the C3 position.   
  
  As summarized in Figure 1.11 lead opitmziation was conducted around a pyrazole urea by 
variation of the N-arly group, urea linker and N-arylpyrzole. A number of urea derivatives were 
produced with a variety of activity on GIRK1/2 found by probing electron withdrawing and 
releasing groups on the “Western” phenyl. Halogens were well tolerated in the meta and para 
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positions where ortho substitution were inactive on the GIRK channel. Electron releasing groups 
such as methoxy and thioether were also tolerated in those positions but with lower potency 
reported than the electron withdrawing groups.  Following up on these reports, the urea nitrogens 
were methylated to determine if available hydrogen bonds were essential for activity. The 
methylated urea probe was determined to be inactive, suggesting hydrogen bonding or sterics had 
a role in binding. Through chemical optimization, ML297 emerged with a very favorable potency 
(EC50 GIRK1/2 = 160nM) reported for a GIRK1 containing GIRK activator.  
 
Key to this GIRK activator probe was the selectivity for GIRK1 containing GIRK channels, 
in addition to being inactive on typical voltage gated K+ ion channels such as KV7.4, inward 
rectifier Kir2.1 and only partially inhibiting hERG with low potency (IC50 ~ 10μM). To fully 
address ML297’s selectivity for GIRK1 containing GIRKs, a radioligand binding assay panel 
failed to show any significant activity on 68 targets with the exception of three receptors (5-HT2b, 
σ1 and  
 
Figure 1.12. a) Raw trace and slopes plotted for CRCs generated from ML297 on GIRK1/2 containing cells. b) No 
activity was reported for GIRK2 containing GIRK channels. c) Gi/o Pertussis (PTX) sensitive G proteins in the 
presence of PTX were exposed to ML297 and positive control glutamate. ML297 still activated GIRK channels where 
glutamate did not.  
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GABAA, ~ 10μM). To follow up on selectivity with GABAA receptors, whole cell voltage-clamp 
studies were performed to confirm that ML297 did not demonstrate any activation of GABA-
invoked currents.  Gi coupled GPCRs are sensitive to pertussis toxin (PTX) treatment and will 
inactivate the αi subunit by ADP-ribosylation. In the presence of PTX, ML297 still was able to 
stimulate activity demonstrated by Tl+ flux assay. These, and the absence of binding from the 
results of the radioligand assay was used to conclude that ML297 is acting directly on the GIRK 
channel to activate it. 
  
 
Figure 1.13. GIRK1 containing GIRK ion channel modulator, VU0456810 (ML297).  
 
The potential for off-target effects, especially for anti-arrhythmic therapeutics was addressed by 
the development of the first selective and potent GIRK 1 containing GIRK modulator, ML297 
(Figure 1.13).  
 
1.4 GIRK Selectivity SAR to Development of “Sulfonamides”  
 Findings with GIRK1 containing GIRK selectivity opened the door to further SAR 
investigation on GIRK1 selective activation. ML297 had allowed some flexibility around the urea 
scaffold to probe the alternate substituents on the aryl, heteroaryl alternatives and varying aliphatic 
groups located at the C3 position of the pyrazole. This was not the case with 2-methylcyclopropyl, 
as there was a strong preference as a GIRK1/2 activator and inactive on GIRK1/4. The only case 
of dual GIRK1/2 and GIRK1/4 activation was the ML297 similar, 3,4-difluoro analog, in which 
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the pyrazole was commercially provided, implied a racemic nature to the 2-methylcyclopropyl. 
Further investigation into the stereoselective nature of GIRK1/2 and GIRK1/4 selectivity can be 
found in Chapter 3.  
 
1.5 Statement of Dissertation  
The work in the following chapters outlines the development and power of molecular tools 
for use in biological investigation. Prior to 2012, there was only a handful of molecular probes that 
would selectively activate GIRK channels. The expansion of this library to include various urea 
and amide derivatives has exponentially increased our understanding of these widely distributed 
ion channels. We have quickly begun to assess GIRK1 selectivity with amide or urea scaffolds 
(Chapter 2) and GIRK1/2 verses GIRK1/4 selectivity with enantiomeric preference (Chapter 3). 
Lately, a dynamic exploration into the world of selectively deprotected dyes for use in GIRK Tl+ 
flux assay has utilized an exogenous enzyme in an engineered cell line (Chapter 4). By developing 
and optimizing molecular tools to overcome high background signal, we can probe how GIRK 
channel activity affects cell function. Through these investigations we can learn about modulation 
of GIRK channels to ultimately set the stage for better pharmaceutical tools to treat debilitating 
neurological disorders.   
 
Parts of this chapter are reprinted with permission from Kaufmann, K.; Romaine, I.; Days, E.; 
Pascual, C.; Malik, A.; Yang, L.; Zou, B.; Du, Y.; Sliwoski, G.; Morrison, R. D.; Denton, J.; 
Niswender, C. M.; Daniels, J. S.; Sulikowski, G. A.; Xie, X.; Lindsley, C. W.; Weaver, C. D., 
ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, 
Displays Antiepileptic Properties in Mice. ACS Chem. Neurosci. 2013, 4, 1278-1286. 
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CHAPTER 2 
DISCOVERY AND SAR OF A NOVEL SERIES OF GIRK1/2 AND GIRK1/4 
ACTIVATORS:  
“SULFONAMIDE SERIES” 
2.1 Introduction 
The G protein-gated Inwardly Rectifying Potassium (K+) (GIRK) channels are a family of 
inward-rectifying potassium channels also known as the Kir3 family, whose physiological role is 
to modulate the excitability of the various cell types in which they are expressed29. Four GIRK 
channel subunits are expressed, as either homo- or heterodimers, in mammals: GIRK1 (Kir3.1), 
GIRK2 (Kir3.2), GIRK3 (Kir3.3) and GIRK4 (Kir3.4). GIRK1–GIRK3 are the predominant 
subunits in the CNS, with GIRK4 expressed at low levels. Multiple lines of evidence support 
important roles for GIRK in a variety of physiological processes including the control of heart rate 
and electrical excitability in a variety of neuronal populations, leading to postulates that GIRK 
channel modulation as a potential therapeutic approach to indications including pain, epilepsy, and 
reward/addiction. However, a complete lack of selective and effective GIRK small molecule 
activators has prevented further validation for GIRK channel modulation as a therapeutic strategy. 
Prior to the work described here the only compounds known to activate GIRK channels were 
ethanol and >100 millimolar concentrations and more recently naringin has been identified as a 
GIRK activator; however, the reported EC50 is in excess of 100 μM30. 
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Figure 2.1 GIRK1 containing GIRK ion channel modulators, original screening hit VU0032230, SAR study probe, 
VU0456810 (ML297), “sulfonamide” scaffold modification to amide, VU0259369, and Narigin a known GIRK 
activator (>100 μM). 
 
Based on the lack of useful chemical matter in the field, Weaver and co-workers seeked to 
develop a suite of channel selective small molecule GIRK modulators. Lead compounds were 
identified by mining high-throughput screening data from an mGlu8 (Metabotropic glutamate 
receptor 8) screening project. In this screen, mGlu8 modulators were identified via a Tl+ flux-based 
readout of GIRK1/GIRK2.11 channels. Once hits for mGlu8 were identified, multiple hits that 
remained were assumed GIRK activators with potencies ranging from ∼1 μM to 10 μM. Two of 
the most promising leads based on activity and chemical tractability were urea VU0032230 and 
sulfonamide VU0259369 (Figure 2.1). We recently reported on optimization of the urea series 
starting from VU0032230, leading to the first selective (∼10-fold vs GIRK1/4, inactive on non-
GIRK1 containing GIRKS and inactive on other K+ channels) GIRK1/2 activator VU0456810 
(aka ML297).  Importantly, ML297 was centrally penetrant and demonstrated anti-epileptic 
properties in mice via GIRK1/2 activation.  
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2.2 Identification and Synthesis of Sulfonamide Analogs 
Sulfonamide VU0259369 proved to act as a dual GIRK1/2 and GIRK1/4 activator showing 
potency of EC50 1.1M on GIRK1/2, efficacy (100%) and EC50 1.1 M on GIRK1/4, efficacy 
(104%). Activity against other GIRK channels was >10 M, respectively31. A generalized 
optimization strategy for sulfonamide ‘369 is shown in Figure 2.1. Our medicinal chemistry plan 
was to very the Eastern arylsulfonamide and Western aryl groups.  The resulting SAR would then 
be combined with modifications of the amide linker with the overall objective of increasing 
potency, selectivity and favorable in vivo properties.32. 
 
 
Figure 2.2 Optimization plan for synthesis of amide and urea derivatives.  
 
In short order, over 100 analogs were synthesized and analyzed using Tl+ flux assays on 
GIRK1/2 and GIRK1/4 expressing cells. A series of analogs of VU ‘369 where the Western 
arylsulfonamide was varied is summarized in Table 2.1. Within this series the SAR proved to be 
shallow with >50% of the analogs displaying no GIRK activity. The iterative parallel synthesis 
effort, surveying modifications to the parent VU ‘369, afforded few actives. Of the actives, 
bromine effectively replaced the chlorine atom, in contrast deletion of the methyl group, 
maintained activity but with diminished potency on GIRK1/4 compared with GIRK1/2. Moving 
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the halogen of 2.4b from the 2- to the 4-position, also led to a diminution in potency at both 
GIRK1/2 and GIRK1/4. Figure 2.3 highlights the GIRK1/2 and GIRK1/4 concentration response 
curves for 2.4b and 2.4a. All attempts to replace or modify the N,N-dimethyl sulfonamide group, 
incorporation of heterocycles or modification of the linker moiety led to a complete loss of GIRK 
activity. Fortunately, the fragment libraries proved more productive (Table 2.2). 
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Tables 2.1 GIRK activity of VU0259369 analogs varied within the Western arylsulfonamide 
 
Compound Ar GIRK1/2 EC50 
(μM) 
GIRK1/4 EC50 
(μM) 
2.2a 
 
>10 >10 
2.2b 
 
5.9 2.7 
2.2c 
 
>10 7.8 
2.2d 
 
>10 >10 
2.2e 
 
>10 0.24 
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2.2f 
 
>10 >10 
2.2g 
 
>10 1.8 
2.2h 
 
>10 2.1 
2.2i 
 
>10 >10 
 
As summarized in Table 2.2 we held the required 5-(N,N-dimethylsulfonamide)-4-methylphenyl 
group constant, and prepared libraries of amide 2.4 and urea congeners 2.5. 
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Tables 2.2. GIRK activity of VU0259369 analogs varied within the Eastern arylsulfonamide. 
 
Compound R/Ar GIRK1/2 EC50 
(μM) 
GIRK1/4 EC50 
(μM) 
2.4a 
 
1.4 1.6 
2.4b 
 
3.3 1.6 
2.4c 
 
2.3 2.2 
2.4d 
 
3.6 5.2 
2.5a 
 
1.4 3.9 
2.5b 
 
3.3 2.8 
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2.5c 
 
2.9 6.2 
2.5d 
 
1.7 5.6 
2.5e 
 
3.9 7.8 
2.5f 
 
1.1 1.8 
2.5g 
 
2.7 6.8 
2.5h 
 
1.5 >10 
2.5i 
 
>10 >10 
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2.3 GIRK Activator CRCs Measuring Tl+ Flux 
 
The amide congeners 2.4a-d proved to be uniformly inactive, with the exception of a few 
C4- to C8-aliphatic amide congeners; however, the GIRK1/2 EC50s were in the 4–10 μM range 
with modest efficacies (23–91%, if ML297 = 100% activity). In contrast, the urea congeners 2.5a-
j possessed robust SAR, low micromolar potencies, high efficacy (71–120%) and engendered a 
slight preference for GIRK1/2 (Table 2.2). This effort provided dual GIRK1/2 and GIRK1/4 
activators such as 2.5b, 2.5f and 2.5j, with a range of full to partial efficacies. This is an important 
finding, as it is not yet clear if a full or partial GIRK activator will be more ideal in terms of in 
vivo efficacy, safety and tolerability, and having a range of chemical tools will enable these issues 
to be addressed. Analogs such as 2.5h, with a 4-CF3 moiety, proved to be selective for GIRK1/2 
(EC50 = 1.5 μM) over GIRK1/4 (EC50 >10 μM), but with low efficacy (26%). Electron rich 
congeners, such as 2.5i, were uniformly inactive at both GIRK1/2 and GIRK1/4. 
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Figure 2.3. GIRK activator concentration response curves (CRC) measuring Tl+ flux. (A) GIRK1/2 (EC50 = 1.1 
lM, 110%) and GIRK1/4 (EC50 = 1.1 lM, 104%) CRCs for the HTS hit 2.4b (Shown as 3); (B) GIRK1/2 (EC50 = 1.4 
lM, 108%) and GIRK1/4 (EC50 = 1.6 lM, 114%) CRC for related analog 2.4a (Shown as 3a). 
 
In analogs 2.2a-i, where the eastern 2-(2-chlorophenyl)acetamide portion was held 
constant and diverse anilines were surveyed, interesting SAR emerged (Table 2.1). SAR was very 
shallow, and unlike analogs 2.5, all analogs 2.2 were devoid of activity at GIRK1/2, affording 
GIRK1/4 preferring activators. A 4-Cl,3-CF3phenyl amide derivative 2.2e, was a very potent 
GIRK1/4 activator (EC50 = 0.24 μM), but displayed weak, partial activation (17%) and was 
inactive on GIRK1/2. Other electron withdrawing substituents in the 3-position, such as Cl (2.2g) 
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or CF3 (2.2h), were selective, partial GIRK1/4 activators; interestingly, electron donating 
substituents in the 3-position, such as 2.2i, were inactive at both GIRK1/2 and GIRK1/4. None of 
the analogs 2.2 or 2.5 were active at non-GIRK1 containing GIRK channels, further enabling them 
as valuable tool compounds to better understand selective GIRK channel activation (see Fig. 2.4). 
  
Figure 2.4. GIRK activator concentration response curves (CRC) measuring Tl+ flux. (A) GIRK1/4 (EC50 = 0.24 
lM, 17%) CRC for 2.2e (Shown as 8e); (B) GIRK1/4 (EC50 = 1.8 lM, 22%) CRCs for 2.2g (Shown as 8g). 
 
 
2.4 Conclusion  
In summary, we have described the synthesis and one of the first accounts of SAR for a 
novel series of rarely described GIRK activators, indicating that GIRK activators can be identified 
from HTS campaigns and optimize their scaffold to improve activity. SAR proved shallow, and 
an iterative parallel synthesis approach provided little improvement in terms of potency or efficacy 
at GIRK1/2 or GIRK1/4. Instead a fragment library approach afforded a diverse array of GIRK 
activators that included dual GIRK1/2 and GIRK1/4 activators, GIRK1/2 preferring activators and 
GIRK1/4 selective activators possessing a wide range of efficacy (from weak partial to full 
activation), and devoid of activity at non-GIRK1-containing GIRK channels. Additional 
characterization and refinements are in progress and will be reported in due course 
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2.5 Experimental  
General Experimental 
All glassware used for reactions was flame dried under vacuum. All reagents and solvents were 
commercial grade and purified prior to use when necessary. All reactions were performed under 
argon atmosphere unless otherwise stated. Diethyl ether (Et2O) and dichloromethane (CH2Cl2) 
were dried by passage through a column of activated alumina using an MBraun MB-SPS dry 
solvent system. Tetrahydrofuran (THF) was distilled from sodium with benzophenone as indicator 
prior to use. 
Reactions were monitored by analytical thin-layer chromatography performed on Analtech silica 
gel GF 250 micron plates. The plates were visualized with UV light (254 nm) and either potassium 
permanganate, ceric ammonium molybdate, or p-anisaldehyde followed by charring on a hot-plate. 
Flash chromatography utilized 230-400 mesh silica gel (SiO2) from Sorbent Technologies or 
Silica RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system. 
Solvents for extraction, washing and chromatography were HPLC grade. 
Nuclear magnetic resonance (NMR) spectra were acquired on either a 300 MHz Bruker DPX-300 
FT-NMR, a 400 MHz Bruker AV-400 FT-NMR, or 500 MHz Bruker DRX-500 FT-NMR 
Spectrometer at ambient temperature. 1H and 13C NMR data are reported as values relative to 
CDCl3. 
1H chemical shifts are reported in  δ values in ppm. Data are reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
integration, coupling constant (Hz). 13C chemical shifts are reported in δ values in ppm. Low 
resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer with 
electrospray ionization. High resolution mass spectra were recorded on a Waters Q-TOF API-US. 
Analytical HPLC was performed on an Agilent 1200 series with UV detection at 214 nm and 254 
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nm along with ELSD detection. Preparative HPLC was conducted on a Gilson 215 Liquid Handler 
HPLC system using Gemini-NX 50 x 20 mm column. 
 
Synthesis of Urea Library 
To a solution of 5-amino-N,N,2-trimethylbenzenesulfonamide (2.3) (15 mg, 0.07 mmol, 1.0 equiv) 
in DMF (1.0 mL) was added an isocyanate (0.07 mmol, 1.0 equiv) at rt. After 12 h, the reaction 
was purified by reverse phase HPLC to afford the desired urea.  
 
Synthesis of Amide Library  
To a solution of 5-amino-N,N,2-trimethylbenzenesulfonamide (2.3) (15 mg, 0.07 mmol, 1.0 equiv) 
in DMF and TEA (4:1, 1.0 mL) was added the acid chloride (0.084 mmol, 1.1 equiv) at rt. Once 
the reaction was complete by LCMS, the reaction was filtered and purified by reverse phase HPLC 
to afford the desired amide. 
 
Tl+ Flux Assay Protocol 
 Compounds were dissolved in DMSO, transferred to 384-well polypropylene plates, and serially 
diluted in DMSO using and Agilent Bravo (11-points, threefold dilutions). Serially diluted plates 
were dispensed to daughter plates using a Labcyte Echo555 and diluted to twofold over their target 
assay concentration with 20 mM HEPES-buffered (pH 7.4) Hanks Balanced Salt Solution (HBSS), 
hereafter referred to as Assay Buffer, using a Thermo Fisher Combi. Twenty-thousand HEK-293 
cells/well stably transfected with the ion channel subunits of interest (e.g., GIRK1/GIRK2, 
GIRK1/GIRK4) were plated into 384-well, black-walled, clear-bottom, amine-coated coated 
plates in 20 μL/well alpha-minimal essential medium (MEM) supplemented with 10% (v/v) fetal 
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bovine serum and incubated overnight in a 5% CO2 incubator at 37 °C. Cell culture medium was 
removedfrom cell plates and replaced with 20 μL/well Assay Buffer. Twenty microliters/well of 
0.5 μM of the Tl+-sensitive dye, Thallos™ -AM (TEFlabs, Austin TX) in Assay Buffer was added 
to cell plates. Cell plates were incubated for ∼60 min at room temperature and then dye-loading 
solution was removed from cell plates and replaced with 20 μL/well Assay Buffer. Dye loaded and 
washed cell plates were transferred to a Hamamatsu FDSS 6000 and a double-addition protocol 
was initiated. After 10s, 20 μL/well of 20 μM test compound in 0.2% DMSO and Assay Buffer 
was added. After 4  min 10 μL/well of a 5× sodium bicarbonate-based Tl+ stimulus buffer (20 mM 
HEPES pH 7.4, 135 mM NaHCO3, 2 mM CaSO4, 1 mM MgSO4,5 mM glucose, 12 mM Tl2SO4) 
was added and 2 more minutes of data collection followed. Fluorescence data were collected at 1 
Hz. 
 
Data Analysis 
Waveform signals (fluorescence intensity vs time normalized by dividing each fluorescence value 
(F) by the initial fluorescence value for each trace (F0)) were reduced to single values by 
subtracting the average normalized waveform from vehicle control wells from each wave on the 
plate followed by obtaining the slope of the change in fluorescence immediately after the addition 
of the Tl+ stimulus. Slope values were normalized as a percentage of the slope obtained by the 
addition of a maximally effective concentration of the GIRK activator, ML297 (e.g., an efficacy 
value of 100% means that the compound’s maximum apparent efficacy equals that of ML297). 
Curve fits for normalized slope values were obtained using a four-parameter logistic equation in 
the Excel add-in, XLfit. 
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Parts of this chapter are reprinted with permission from Ramos-Hunter, S. J.; Engers, D. W.; 
Kaufmann, K.; Du, Y.; Lindsley, C. W.; Weaver, C. D.; Sulikowski, G. A., Discovery and SAR 
of a novel series of GIRK1/2 and GIRK1/4 activators. Bioorg. Med. Chem. Lett. 2013, 23, 5195-
5198. 
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CHAPTER 3 
DISCOVERY OF A STEREO-SPECIFIC MODULATION OF GIRK1/2 AND GIRK1/4 
CHANNELS:  
SYNTHESIS AND EVALUATION OF 2-METHYLCYCLOPROPYL ENANTIOMERS 
3.1 Introduction  
G protein-gated inwardly rectifying potassium (GIRK) channels are part of a larger family 
of inwardly rectifying potassium channels (Kirs) that regulate diverse biological processes. Kirs 
regulate solute balance in the kidneys, cardiac rates and rhythms, and neuronal excitability. 
Specifically, dysfunction in GIRKs expressed throughout the central nervous system (CNS) have 
been linked to schizophrenia, pain perception, drug addiction, and epilepsy. Research into GIRK 
channels has been limited due to lack of selective and potent small molecule probes. Recently, a 
high throughput screen followed by SAR studies has led to the identification of a GIRK activator, 
VU810 (aka ML297) found to selectively activate GIRK1 containing channels. During the course 
of SAR studies, it was discovered that one enantiomer of unknown absolute configuration of a 
chiral analog of ML297 displayed high GIRK1/2 selectivity. This compound’s ability to 
discriminate between the major brain (GIRK1/2) and cardiac (GIRK1/4) GIRK ion channels is 
significant in determining the therapeutic potential of these ion channel targets. In this chapter we 
describe the asymmetric synthesis of the GIRK1/2 selective enantiomer leading to the assignment 
of its absolute stereochemistry as S,S. Several single enantiomer probes were prepared around the 
core scaffold and found to act as selective GIRK1/2 activators and GIRK1/4 inhibitors. Our 
understanding of function and regulation of GIRK channels continues to improve with the 
identification of new potent and channel selective probes to guide the therapeutic potential of 
modulating GIRK channels.  
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3.2 Background  
Potassium channels are key regulators of excitability in numerous excitable tissues 
including neurons, cardiomyocytes, and hormone-secreting endocrine cells. In particular, the G-
protein-gated inward rectifying potassium channel (GIRK) is believed to play an important role in 
setting cellular membrane potential and in doing so effect neuron firing, heart rate, and hormone 
secretion1. GIRK activity can be regulated, as its name suggest by the activity of G-protein-coupled 
receptors (GPCR). The Gi/o coupled G-protein-coupled receptors (GPCR) class of receptors can 
mediate activation of GIRK via the β/γ-subunits3 of the heterotrimeric G-protein and thus 
activation of the GPCR is able to affect GIRK’s ability to modulate cellular excitability. In addition 
to GIRK activation by Gi/o GPCRs, the channel can also by modulated by changes in plasma 
membrane phosphatidylinositol 4,5-bisphosphate levels, by phosphorylation, and by small 
molecules. The GIRK family is comprised of four members, Kir3.1-Kir3.4 (aka GIRK1-GIRK4)5. 
These four family members can assemble into a variety of homo and heterotetrameric 
configurations to yield channels with different biophysical properties and different tissue 
distributions1. In the central nervous system the predominant subunit conformation is the GIRK1/2 
heterotetramer while GIRK1/4 in atrial cardiomyocytes, in L-cells of the gut, in the adrenal gland, 
and in other tissues. Non-GIRK1-contaning GIRKs have more limited expression in localized 
brain regions such as the ventral tegmental area28. Genetic manipulation of GIRK expression in 
mice has revealed a number of potential functions of GIRK in physiological/pathophysiological 
processes including epilepsy, anxiety, pain, and drug addiction. In addition, numerous studies point 
GIRK’s involvement in a range of disorders such as epilepsy, Down’s syndrome, alcoholism, 
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schizophrenia, hyperaldosteronism, atrial fibrillation, responsiveness to opioid analgesics, and 
others. A full review of GIRK’s involvement can be found in reference1. 
 
Figure 3.1. Functionalization around ML297 (left). Initially, 3,4-diFluoro was found to be an excellent activator of 
GIRK1 containing GIRK channels. Recently, selectivity studies have probed the C3 position on the pyrazole to 
determine GIRK1 containing selectivity and pursued a diversifying SAR (right).  
 
Recently we demonstrated for the first time that it was possible to modulate the activity of 
GIRKs through the direct action of small molecule activators and inhibitors. Lead optimization led 
to the development of the GIRK1 selective activator ML297 (GIRK1/2 EC50 = 0.16 μM, Figure 
3.1)9. ML297 and analogs possess the peculiar property of only changing the activity of GIRK1-
containing GIRKs. We have discovered two key amino acids in GIRK1 that appear to be 
responsible for this exquisite subunit selectivity33. When our small molecule modulators of 
GIRK1-containing GIRKs have been tested in vivo we have observed concentration- dependent 
effects in murine models of epilepsy9, stress induce hyperthermia, and elevated plus maze34. These 
data suggest a potential role for pharmacological modulation of GIRK for the treatment of a 
number of disorders. Although molecules like ML297 are useful molecular tools, there are issues 
with them that limit their utility as pharmacological tools. Most notably ML297 is ~6-10f fold 
more selective for GIRK1/2 which limits ability to evaluate the therapeutic potential of GIRK1 
containing GIRK channels as GIRK1/4 is expressed in cardiac and other peripheral tissues. During 
the course of SAR studies of ML297 we observed the pyrazole C3 position to be a “hot spot” as 
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variation of substituents at this position led to significant changes in functional activity as well as 
potency (vide infra). 
 
GIRK1/2 Verses GIRK1/4 Selectivity Studies  
 Wen and coworkers35 proceeded to identify additional GIRK activators and “molecular 
switches” which were found to be the first examples of selective GIRK inhibitors. Holding the 3-
methyl pyrazole and the 3,4-difluorophenyl aryl group constant, the N-Ph alternatives were 
explored. Here they uncovered one of the most potent GIRK1 activator, the N-benzyl derivative 
(GIRK1/2 EC50= 0.07 μM, GIRK1/4 EC50= 0.11 μM). 
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Table 3.1 Structures and activity of GIRK probe analogs on GIRK1/2 and GIRK1/4. Potency values reported as 
μM and obtained from triplicate determinations. NA = not determined. 
 
Compound R group GIRK1/2 
EC50 (μM) 
GIRK1/2  
IC50 (μM) 
GIRK1/4 
EC50 (μM) 
GIRK1/4 
IC50 (μM) 
3.1a  
 
>30 30 30 30 
3.1b 
 
0.41 NA 30 NA 
3.1c 
 
NA 2.0 NA 1.4 
3.1d 
 
30 30 30 30 
3.1e 
 
NA 5.1 NA 4.1 
3.1f 
 
30 30 30 30 
3.1g 
 
NA 0.65 NA 0.56 
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Changes in the pyrazole C3 subsitution starting from commercial N-phenyl pyrazoles 
provided an equally rich span of activity and selectivity (Table 3.1). Unique to this series was the 
uncovering of the “molecular switch” of a cyclopropyl group as a GIRK1/2 activator derivative 
(GIRK1/2 EC50= 0.41 μM, GIRK1/4 EC50= 30 μM) and an iso-propyl GIRK1 inhibitor (GIRK1/2 
IC50= 2.0 μM, GIRK1/4 IC50= 1.4 μM). Surprisingly, the cyclobutyl substitution was inactive on 
both GIRK1/2 and GIRK1/4, leading to the consideration that slight structural modification can 
determine GIRK1 selectivity in the pyrazole region. The SAR was further explored with a variety 
of isocyanate coupling partners for N-phenyl or benzyl pyrazoles bearing an iso-propyl, 
cyclopropyl or cyclobutyl. A wide range of selectivity and activity emerged, but most notably, the 
iso-propyl were exclusively inhibitors and active with a preference for GIRK1/4. Based on the 
previous report, the C3 position on the pyrazole had eluded to some degree of GIRK1 selectivity 
We have described a series of compounds based on the ML297 structure that display a strong 
preference for activation of GIRK1/2 over GIRK1/4. Among these molecules are a family of 
substituted cyclopropanes. Coupling with a commercially provided 2-methyl cyclopropyl 
pyrazole, probe derivatives were synthesized and surveyed with a variety of aryl pendant groups 
(Table 3.2).  Switching the methyl from 1-methyl cyclopropyl to 2-methyl cyclopropyl analogs 
displayed activator activity as opposite to inhibitor, suggesting a high degree of selectivity around 
the C3 position on the pyrazole.  
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Table 3.2 Structures and activity of GIRK probe analogs on GIRK1/2 and GIRK1/4. Potency 
values reported as μM and obtained from triplicate determinations. NA = not determined. 
 
 
Compound R group GIRK1/2  
EC50 (μM)  
GIRK1/2 
 IC50 (μM) 
GIRK1/4  
EC50 (μM) 
GIRK1/4  
IC50 (μM) 
3.2a 
 
0.44 NA 0.89 NA 
3.2b 
 
0.46 NA >10 NA 
3.2c 
 
0.85 NA 2.2 NA 
3.2d 
 
0.89 NA >30 NA 
3.2e 
 
1.3 NA 2.3 NA 
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3.2f 
 
1.9 NA >30 NA 
3.2g 
 
3.0 NA >30 NA 
3.2h 
 
>30 NA >30 NA 
 
Because some of the molecules in question possess chiral centers and because the samples we 
tested were a racemic mixture, we were interested in determining whether there might be a stereochemical 
bias for their GIRK1/2 vs GIRK1/4 selectivity.  After assaying a racemic mixture of 2-methyl cyclopropyl 
analogue 3.2a (presumed to possess trans relative stereochemistry about the cyclopropyl ring), those data 
suggested a higher selectivity for GIRK1/2 (EC50 = 0.440 μM) channels when compared to GIRK1/4 
(EC50 = 0.890 μM). The mixture was resolved by chiral LC and one enantiomer proved to be significantly 
more potent in activating GIRK 1/4 channels relative to the second. In order to assign the absolute 
configuration of the GIRK1/4 selective enantiomer we set out to prepare optically pure isomers of 3.2a 
using a well-defined synthetic route. The individual enantiomers were then assayed using for GIRK 
channel selectivity using HEK-293 cells expressing either GIRK1/2 or GIRK1/4 using the Tl+ flux assay.  
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3.3 Synthesis of trans 2-Methyl Cyclopropyl Enantiomer Probes  
 
 
Figure 3.2. Preparation of single enantiomer methylcyclopropranes. 
The most common synthesis of aminopyrazoles is the condensation of beta-ketonitriles with 
hydrazines. For the preparation of aminopyrzazoles (R,R)-3.5 this requires beta-ketonitrile 3.4. The latter 
would be readily derive cyclopropanecarboxylic acid (R,R)-3.3. Conversely, aminopyrazole (S,S)-3.5 will 
be derived form (S,S)-3.3. Our first objective became the asymmetric synthesis of (R,R)-3.3 and (S,S)-
3.3. Examination of the literature immediately identified the Mori method36 for the preparation of the two 
enantiomeric cyclopropanecarboxylic acids as the optimal preparation  of optically material37.  
The Mori procedure starts with the trans acetalization of crotonaldehyde diethyl acetal with readily 
available (+)- or (-)-diisopropyl tartrate leading to optically carboxylic acid 3.3 of either absolute 
configuration depending of the starting tartrate ester. The reaction sequence is illustrated for (R,R)-3.3 
starting from (+)-DIPT. The key Simon-Smiths cyclopropanation occured in high yields (70-85%) and 
>95% diastereoselectivity based on NMR analysis36 . Oxidation of the acetal 3.8 with ozone provided 
ester 3.9 which upon saponification gave cyclopropane carboxylic acid (R,R)-3.337.  The latter was 
converted to Weinreb amide 3.10 and reacted with the anion derived from acetonitrile to provide beta-
ketonitrile 3.4. Condensation of 3.4 with phenylhydrazine gave aminopyrazole (R,R)-3.5 as a single 
enantiomer product ([α]20D -25.2 (c 2.50 ethanol)) . Following the identical synthetic route starting form 
(-)-DIPT afforeded the enantiometric aminopyrazole (S,S)-3.5 ([α]20D +22.8 (c 1.25, ethanol).). 
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Aminopyrazoles (S,S)- and (R,R)-3.5 were individually condensed with 3,4-difluorophenyl isocyanate to 
give (S,S)- and (R,R)-3.2a which were subsequently evaluated in the Tl+  flux assay. 
 
 
Scheme 3.1. Synthesis of 2-methylcyclopropyl (R,R) or (S,S) enantiomers.  Trans 2-methyl cyclopropyl carbocyclic acid 
enantiomers were prepared following the work of Mori and coworkers39
 
3.4 Cyclopropyl Enantiomer CRCs Measuring Tl+ Flux 
Using the Panoptic kinetic imaging plate reader in the Vanderbilt University High-Throughput 
Screening facility, Human Embryonic Kidney (HEK-293) cells expressing GIRK1/2 or GIRK1/4 
channels were assayed using serial dilutions of the urea enantiomers and ML297 as a standard (Detailed 
procedure found in Experimental). The raw traces for compound efficacy (normalized to %ML297Max, 
Figure 3.4) over time showed an enantiomer (1R,2R) preference for GIRK1/2 over GIRK1/4. Not 
surprisingly, the enantiomers were all active on GIRK1/2 but an interesting relationship developed with 
GIRK1/4. Those channels show activator selectivity preference for (3,4-difluoro) VU0657405 3.11a 
(GIRK1/2 = 0.79μM, GIRK1/4 = 1.1μM) verses VU0657424 3.11b (GIRK1/2 = 0.63μM, GIRK1/4 
inactive) enantiomers. We now have a GIRK1 selective probe that is preferentially active for GIRK1/2 to 
use in our molecular toolbox. To our astonishment, we also identified isomers with inhibitor selectivity 
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VU0657532 3.12b (GIRK1/2 = 1.8μM, GIRK1/4 inhibitor = 2.0μM) verses VU0659392 3.12a (GIRK1/2 
= 0.87μM, GIRK1/4 inactive) enantiomer. Just as we had seen with the racemic data, activity for a single 
enantiomer dropped off dramatically with GIRK1/4 channels. This “molecular switch” probe 3.12b would 
act to inhibit GIRK1/4 and activate GIRK1/2 (See Figure 3.3). 
 
 
Figure 3.3. Single enantiomer ureas: VU0659392(3.12a), VU0657532(3.12b), VU0657405(3.11a), and 
VU0657424(3.11b). 
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To further validate these results from Tl+ flux assay, electrophysiology was recorded for the 2-
methylcyclopropyl enantiomers on GIRK1/2 and GIRK1/4 channels. Using (1S,2S), VU0657532 
demonstrated selectivity preference for GIRK1/2 as an activator and GIRK/14 as an inhibitor.  
 
Figure 3.4. Tl+ flux of GIRK1/2 (left) and GIRK1/4 (right) with compounds 3.11a-3.12b, standardized to ML297 
fluorescence intensity.  A) Raw Tl+ activity trace of GIRK1/2 channels demonstrating activation by MCP enantiomers. B) Raw 
Tl+ activity trace of GIRK1/4 channels. One enantiomer (VU0657532) acts as an inhibitor. C) Concentration Response Curve 
(CRC) of MCP enantiomers on GIRK1/2 channels. D) CRC of MCP enantiomers on GIRK1/4 channels 
 
 
 
 
  
46 
 
 
Table 3.3. EC50 and IC50 (μM) of MCP Isomers on GIRK1/2 and GIRK1/4 channels. 
 
Compound VU Number Isomer GIRK1/2 
EC50 (μM) 
GIRK1/2 
IC50 (μM) 
GIRK1/4 
EC50 (μM) 
GIRK1/4 
IC50 (μM) 
 VU0456810 
(ML297) 
 0.16 NA 1.8 NA 
3.12a VU0659392 (R,R) 0.87 NA NA NA 
3.12b VU0657532 (S,S) 1.8 NA NA 2.0 
3.11a VU0657405 (R,R) 0.79 NA 1.1 NA 
3.11b VU0657424 (S,S) 0.63 NA NA NA 
3.5 Conclusion 
Research into GIRK channels has been limited due to lack of selective and potent small molecule 
probes. During the course of SAR studies a highly GIRK1/2 selective enantiomer was discovered 
following chiral LC resolution. Preparation of single enantiomers of known configuration and results of 
channel selective activation and inhibition are shown. These enantiomer probes were found to all act as 
GIRK1/2 activators but with varying activity on GIRK1/4. One enantiomer, VU0657532 (3.12a) was 
found to contain a configuration “molecular switch”, acting as an activator on GIRK1/2 and inhibitor on 
GIRK1/4. These results from Tl+ flux assay were validated using (electrophysiology).  The ability to 
preference GIRK1 selectivity has been generously driven in the correct direction with MCP probes from 
the initial non-selective GIRK1 activator, ML297. To capture both GIRK1 selectivity and potency, further 
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SAR studies should be conducted on the MCP scaffold, such as investigating the cis geometry or 
additional chiral pendant groups. Our understanding of function and regulation of GIRK channels will 
improve with better chemically-synthesized products; potent and selective small molecules will guide the 
therapeutic potential of modulating GIRK channels. On-going work in this area will define our 
understanding of GIRK1 containing GIRK channels through selective activation. We could potentially 
use the scaffold of these probes as GIRK1 active pharmaceutical lead compounds.  
 
3.6 Experimental  
General Experimental 
All glassware used for reactions was flame dried under vacuum. All reagents and solvents were 
commercial grade and purified prior to use when necessary. All reactions were performed under argon 
atmosphere unless otherwise stated. Diethyl ether (Et2O) and dichloromethane (CH2Cl2) were dried by 
passage through a column of activated alumina using an MBraun MB-SPS dry solvent system. 
Tetrahydrofuran (THF) was distilled from sodium with benzophenone as indicator prior to use. 
Reactions were monitored by analytical thin-layer chromatography performed on Analtech silica 
gel GF 250 micron plates. The plates were visualized with UV light (254 nm) and either potassium 
permanganate, ceric ammonium molybdate, or p-anisaldehyde followed by charring on a hot-plate. Flash 
chromatography utilized 230-400 mesh silica gel (SiO2) from Sorbent Technologies or Silica RediSep Rf 
flash columns on a CombiFlash Rf automated flash chromatography system. Solvents for extraction, 
washing and chromatography were HPLC grade. 
Nuclear magnetic resonance (NMR) spectra were acquired on either a 300 MHz Bruker DPX-300 FT-
NMR, a 400 MHz Bruker AV-400 FT-NMR, or 500 MHz Bruker DRX-500 FT-NMR Spectrometer at 
ambient temperature. 1H and 13C NMR data are reported as values relative to CDCl3. 
1H chemical shifts 
are reported in δ values in ppm. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). 13C 
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chemical shifts are reported in δ values in ppm. Low resolution mass spectra were obtained on an Agilent 
1200 series 6130 mass spectrometer with electrospray ionization. High resolution mass spectra were 
recorded on a Waters Q-TOF API-US. Analytical HPLC was performed on an Agilent 1200 series with 
UV detection at 214 nm and 254 nm along with ELSD detection. Preparative HPLC was conducted on a 
Gilson 215 Liquid Handler HPLC system using Gemini-NX 50 x 20 mm column. 
 
Synthesis of (R,R) and (S,S) trans 2-methyl Cyclopropyl Phenyl Pyrazole Urea Enantiomers 
Note: Trans 2-methyl cyclopropyl carbocyclic acid enantiomers were prepared following the work of 
Mori and coworkers36.  
 
(1R,2R)-N-methoxy-N,2-dimethylcyclopropanecarboxamide. To a solution of 3.337 (1.6 g, 15.99 
mmol) in DCM (10 mL) were added freshly distilled oxalyl chloride (1.65 mL, 19.19 mmol) and a 
catalytic amount of dimethylforamide. The mixture was stirred until gaseous bubbles ceased evolving and 
excess oxalyl chloride was removed in vacuo. The residue was dissolved in DCM (10 mL). To the solution 
was added N,O-dimethylhydroxylamine hydrochloride (2.34 g, 24.0 mmol) followed by pyridine (5.16 
mL). The mixture was stirred until judged complete by TLC (1:1 hex/EtOAc). When complete, reaction 
was quenched with 2M HCl (20 mL) and extracted with EtOAc (3X50mL). Organic layer was combined, 
dried over MgSO4, and concentrated in vacuo to yield a crude yellow oil. The residue was purified by 
vacuum distillation (b.p. 35-40oC at 10 Torr ) to yield 700 mg (30% over two steps) of  Weinreb amide 
3.10 as a colorless oil: [α]20D -38.2 (c 1.31, ethanol); 1H NMR (400 MHz, CDCl3): δ 3.73 (s, 3H), 3.19 (s, 
3H), 1.83 (m, 1H), 1.34 (m, 1H), 1.65 (q, J = 5.1 Hz, 1H), 1.12 (d, J = 6.0 Hz, 3H), 0.63 (m, 1H). 13C 
NMR (400 MHz, CDCl3): δ16.2, 16.6, 17.9, 18.5, 32.5, 61.4, 174.4.  
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(1S,2S)-N-methoxy-N,2-dimethylcyclopropanecarboxamide. Following the above procedure. 
The residue was purified by vacuum distillation (b.p. 35-40oC at 10 Torr ) to yield 615mg (30% over two 
steps) of the Weinreb amide as a colorless oil identical to R,R isomer except for optical rotation: [α]20D 
+32.7 (c 1.13, ethanol). 
 
3-((1R,2R)-2-methylcyclopropyl)-3-oxopropanenitrile. To a solution of acetonitrile (0.24 mL, 4.54 
mmol) and THF (2.3 mL) cooled to -78 oC was added dropwise 12.2 mL of 1M lithium 
bis(trimethylsilyl)amide in THF. The reaction mixture was stirred at -78 oC for 1h and a solution of  0.500 
g  (3.49 mmol) of Weibreb amide 3.10 in THF (2.5 mL) was added drop wise. The solution was stirred 
for an additional 1 h at -78 oC and allowed to  warm to room temperature. The reaction mixture was 
quenched with Sat. NH4Cl (5.0 mL) and the mixture extracted with EtOAc (3X25 mL). The combined 
organic extracts were dried over MgSO4, and concentrated in vacuo to yield a crude brown oil. The 
residue was purified by column chromatography with hexane/ethyl acetate (10% to 30%) to yield 342.5 
mg (80%) of β-keto nitrile 3.4 as a colorless oil: [α]20D -126.0 (c 1.50, ethanol); 1H NMR (400 MHz, 
CDCl3): δ3.55 (s, 2H), 1.85 (quintet, J = 4.05 Hz, 1H), 1.59 (m, 1H), 1.42 (m, 1H), 1.17 (d, J = 6.20 Hz, 
3H), 0.94 (m, 1H). 13C NMR (400 MHz, CDCl3): δ17.8, 21.2, 22.7, 28.9, 32.6, 114.0, 196.9.  
3-((1S,2S)-2-methylcyclopropyl)-3-oxopropanenitrile. Following the above procedure. The 
residue was purified by column chromatography with hexane/ethyl acetate (10% to 30%) to yield 100.1 
mg (60%) of β-keto nitrile as a colorless oil identical to RR isomer except for optical rotation: [α]20D 
+122.0 (c 1.50, ethanol). 
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3-((1R,2R)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-amine. To a solution of 3.4(100.0 mg, 0.81 
mmol), p- TsOH(0.1 mmol) and phenylhydrazine (0.11 mL, 0.81 mmol) in ethanol (1M) was heated to 
reflux until determined judged complete by TLC (1:1 hex/EtOAc). The mixture was concentrated in 
vacuo, washed with saturated NaHCO3 (15 mL) solution and extracted with EtOAc. (3X25 mL). The 
organic layers were combined, dried over MgSO4 and concentrated to yield a crude orange oil. The 
residue was purified by column chromatography with hexane/ethyl acetate (20% to 50%)to yield 100.5mg 
(60%) of 2-methyl cyclopropyl pyrazole 3.5 as an orange solid: [α]20D -25.2 (c 2.50 ethanol); 1H NMR 
(400 MHz, CDCl3): δ7.53 (m, 2H), 7.43 (t, J = 7.46 Hz, 2H), 7.29 (t, J = 7.46 Hz, 1H), 5.24 (s, 1H), 3.71, 
(s, 2H), 1.58 (sextet, J = 4.42 Hz, 1H), 1.14 (d, J = 5.25 Hz, 3H) 1.08 (m, 1H), 0.880 (m, 1H), 0.663 (m, 
1H). 13C NMR (400 MHz, CDCl3): δ16.1, 16.3, 18.1, 18.7, 86.9, 123.8, 126.9, 129.4, 138.7, 145.0, 155.8. 
LCMS calculated for C13H15N3 (M+H)+ m/z: 213.3, Measured 214.7 m/z.  
3-((1S,2S)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-amine. Following the above procedure. The 
residue was purified by column chromatography with hexane/ethyl acetate (20% to 50%) to yield 35.5mg 
(40%) of the 2-methyl cyclopropyl pyrazole as an orange solid identical to RR isomer except for optical 
rotation: [α]20D +22.8 (c 1.25, ethanol). 
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1-(3,4-difluorophenyl)-3-(3-((1R,2R)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-yl)urea. To a 
solution of 3.5 (100.0mg, 0.47 mmol) in 1.56 mL of dichloromethane was added 3,4-difluorophenyl 
isocynate (0.11 mL, 0.94 mmol) and allowed to stir overnight. The mixture was concentrated in vacuo to 
yield an off-white solid. The solid urea was purified by column chromatography with hexane/ethyl acetate 
(20% to 50%) to yield 103.0 mg (60%) of the 2-methylcyclopropyl pyrazole urea 3.11a as a white solid, 
mp 175-176oC. [α]20D -30.7 (c 1.30, ethanol); 1H NMR (400 MHz, DMSO): δ9.17 (s, 1H), 8.46 (s, 1H), 
7.60 (ddd, J = 7.56, 6.55, 6.00 Hz, 1H), 7.49 (m, 4H), 7.39 (m, 1H), 7.31 (q, J = 9.03, 10.42 Hz, 1H), 7.06 
(m, 1H), 6.13 (s, 1H), 1.59 (qu, J = 4.00, 4.84 Hz, 1H), 1.13 (d, J = 5.57 Hz, 3H), 0.873 (m, 1H), 0.697 
(m, 1H). 13C NMR (400 MHz, DMSO): δ16.2, 16.3, 18.1, 18.9, 96.4, 107.4-107.6, 114.8, 117.7-117.9, 
124.5, 127.6, 129.6, 136.8-136.9, 137.4, 138.8, 143.7-143.8, 146.1, 148.2- 148.3, 150.7, 152.1, 154.6. 
LCMS calculated for C20H18F2N4O (M+H)+ m/z: 368.4, Measured 369.1 m/z.  
1-(3,4-difluorophenyl)-3-(3-((1S,2S)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-yl)urea. 
Following the above procedure The solid urea was purified by column chromatography with hexane/ethyl 
acetate (20% to 50%) to yield 41.0mg (80%) of the 2-methylcyclopropyl pyrazole urea as a white solid 
identical to RR isomer except for optical rotation: [α]20D +39.0 (c 1.10, ethanol). 
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1-(3-((1R,2R)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4-(trifluoromethyl)phenyl)urea. 
To a solution of 3.5 (25.0mg, 0.12 mmol) in 0.40 mL of dichloromethane was added 3,4-difluorophenyl 
isocynate (0.03 mL, 0.24 mmol) and allowed to stir overnight. The mixture was concentrated in vacuo to 
yield an off-white solid. The solid urea was purified by column chromatography with hexane/ethyl acetate 
(20% to 50%) to yield 43.0 mg (86%) of the 2-methylcyclopropyl pyrazole urea 3.12a as a white solid, 
mp 160-163oC: [α]20D -17.3 (c 3.00, ethanol); 1H NMR (400 MHz, DMSO): δ9.33 (s, 1H), 8.51 (s, 1H), 
7.95 (s, 1H) 7.52 (m, 6H), 7.40 (m, 1H), 7.31 (d, J = 8.00 Hz, 1H), 6.16 (s, 1H), 1.59 (qu, J = 4.00, 4.84 
Hz, 1H), 1.13 (d, J = 5.57 Hz, 3H), 0.873 (m, 1H), 0.697 (m, 1H). 13C NMR (400 MHz, DMSO): δ16.2, 
16.3, 18.2, 18.9, 96.4, 114.5-114.6, 118.8, 121.9- 127.3, 122.2, 124.6, 127.7, 129.6, 129.8, 130.4, 137.40, 
138.8, 140.7, 152.2, 154.7. LCMS calculated for C21H19F3N4O (M+H)+ m/z: 400.2, Measured 401.2 m/z.  
1-(3-((1S,2S)-2-methylcyclopropyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(trifluoromethyl)phenyl)urea. 
Following the above procedure The solid urea was purified by column chromatography with hexane/ethyl 
acetate (20% to 50%) to yield 71.0 mg (63%) of the 2-methylcyclopropyl pyrazole urea as a white solid 
identical to RR isomer except for optical rotation: [α]20D +18.0 (c 1.10, ethanol) 
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APPENDIX 
NMRS FOR CHAPTER 3 
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Figure 3.5. 1H-NMR spectrum (400 MHz, CDCl3) of 1R,2R 3.10, 1H-NMR spectrum (400 MHz, CDCl3) of 1S,2S 3.10b 
and 13C-NMR spectrum (400 MHz, CDCl3) of 1R,2R 3.10. 
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Figure 3.6. 1H-NMR spectrum (400 MHz, CDCl3) of 1R,2R 3.4, 1H-NMR spectrum (400 MHz, CDCl3) of 1S,2S 3.4b and 
13C-NMR spectrum (400 MHz, CDCl3) of 1R,2R 3.4. 
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Figure 3.7. 1H-NMR spectrum (400 MHz, CDCl3) of 1R,2R 3.5, 1H-NMR spectrum (400 MHz, CDCl3) of 1S,2S 3.5b and 
13C-NMR spectrum (600 MHz, CDCl3) of 1R,2R 3.5. 
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Figure 3.8. 1H-NMR spectrum (400 MHz, DMSO) of 1R,2R 3.11a, 1H-NMR spectrum (400 MHz, DMSO) of 1S,2S 
3.11b and 13C-NMR spectrum (600 MHz, DMSO) of 1R,2R 3.11a. 
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Figure 3.9. 1H-NMR spectrum (400 MHz, DMSO) of 1R,2R 3.12a, 1H-NMR spectrum (400 MHz, DMSO) of 1S,2S 
3.12b and 13C-NMR spectrum (600 MHz, DMSO) of 1R,2R 3.12a. 
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CHAPTER 4 
SELECTIVE RHODAMINE PRO-DYE/ENZYME RELEASING PAIR: MITOCHONDRION 
MEMBRANE POTENTIAL SENSORS 
4.1 Introduction 
A powerful molecular tool used in biological assays has been organic fluorophores. Fluorogenic 
molecules have shown broad utility as reporter tags, sensors and cellular dyes14. A comprehensive 
collection of fluorogenic core scaffolds include fluorescein, which was first synthesized in 1871 spanning 
to the recently developed boron dipyrromethene (BODIPY) dyes, where all scaffolds have varying optical 
and physical properties. A variety of fluorogenic molecules that emit in the ultra-violet to near infra-red 
spectrum and offer varying scaffolds for useful applications such as organelle localization (i.e. rhodamines 
localizing to the mitochondria)38. The most common fluorogenic scaffold is xanthene-based, also known 
as fluorescein. Fluorescein spirolactones have a unique pH sensitive on-off equilibrium, shifting between 
a closed non-fluorescent lactone and an open fluorescent carboxylate-quinoid structure14. The 
introduction of electron withdrawing groups on the phenol containing rings, such as halogenation can 
lower the phenolic pKa and drive the equilibrium towards the fluorescent quinoid16. The non-fluorescent 
spirolactone can be “locked” by phenol protection such as acetylation.  
A recent renaissance of dye synthesis and application has extended to the unique properties of 
xanthene scaffolds. Examples include replacing the oxygen on the xanthene scaffold with a dimethyl silyl 
group and effectively red-shifted the emission of the fluorescent molecule (2-Me, ToykoMagenta (TM)).  
Also, upon replacement of the carboxylic acid with a methyl, dubbed ToykoGreen, further red-shifts the 
emission wavelength8. In addition to changing spectral properties of dyes, modifications to the core 
scaffold have resulted in chemical on “switches” and reversible photo switching. These dyes have been 
used as enzymatic sensors by indicating specific cellular activities with increasing fluorescence through 
the selective “unmasking” or removal of a protection group on the phenol or aniline group. Previous 
63 
 
examples have focused in protein specific, light or pH dependent activation to real-time imaging, the 
spatial exploration of cellular machinery and high resolution imaging of live cells. This study explores 
the potential of engineering cells for pro-dye/enzyme selectivity paring, (e.g. caged dyes) to overcome 
issues of non-selective fluorescence that currently impairs our cellular assays.  
4.2 Background 
Metal Ion Sensor Dyes  
Notably, one of the most popular and well defined metal ion probes were Ca2+ sensors developed 
by Tsien24. Using the novel chelator, 1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid 
(BAPTA, Figure 4.1), improved previously known chelators by modifying the pKa of the amine moieties
39 
and allowed Ca2+ to chelate at physiological pH. Fluorescent probes with the BAPTA chelator then were 
developed, markedly Oregon Green 488 BAPTA-1 for dendritic Ca2+ detection40.  Metal sensors for K+ 
and Na+ have also been developed, such as potassium-binding benzofuran isophthalate (PBFI) which 
contains a 18-crown-6 chelator but suffers from low quantum yield and poor selectivity for K+ over Na+. 
To address this, a rhodamine scaffold (Figure 4.1) was tied to a modified 18-crown-6 scaffold, known as 
2-triazacryptand[2,2,3]-1-(2-methoxyethoxy)benzene (TAC)41 which offers improved selectivity and 
quantum yield. After first exploring with the chelating abilities of coumarin benzothiazole (BTC), 
FluoZin, originally a Zn2+ dye, presented dequenching metal sensing upon the addition of Tl+ with the N-
(2-methoxyphenyl)iminodiacetate chelation subunit. The addition of Tl+ dequenched the fluorescence and 
presented a brighter form of the dye. 
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Figure 4.1. (Left)1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA) developed by Tsien chelates Ca2+. 
(Right) 2-triazacryptand[2,2,3]-1-(2-methoxyethoxy)benzene (TAC-RED) are selective for K+. 
 
The requirement of a metal sensor that permitted a brighter fluorophore with Tl+ drove towards the 
development of Thallos™ 13, a BAPTA-AM hybrid linked to a xanthene fluorophore. 
 
“Protected” Dyes Used For Enzymatic Studies  
Using fluorogenic substrates to measure catalytic efficiency of enzymes has been well established 
in the latter half of the 21st century. Coumarin, a benzopyrone dye scaffold commonly emitting in the 
blue-green spectrum (>450 nm) is an early example of a modified peptide substrate used to measure 
enzymatic properties. The activity of trypsin, chymotrypsin and elastase were elucidated by coupling 7-
amino-4-methylcoumarin with peptide chains specific to their respective enzyme substrate42. Fluorescein 
and rhodamine dyes have also been previously utilized in enzyme activity assays. Fluorescein, when 
acetylated, produces the readily hydrolyzed ester by cellular esterases.  Rhodamine amide protecting 
groups are not easily hydrolyzed and provide a resistant alternative with similar xanthene fluorescent 
properties.  Previously, Lavis and coworkers had identified Porcine Liver Esterase (PLE) as a 
promiscuous hydrolase to activate their “trimethyl lock” (Figure 4.2) and release their modified 
rhodamine43. Originally, the trimethyl lock moiety had been installed to combat spontaneous hydrolysis 
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in aqueous solutions. Their substrate was well tolerated by PLE (Kcat/KM =8.2 X10
5 M-1s-1) and suggested 
that it may accommodate a variety of amide functionalities. Pig or Porcine Liver Esterase (PLE) is a 
carboxyl esterase that has had previous applications as a biocatalyst44. The heteromeric enzyme is 
composed of three subunits (α, β, γ) and exists as a trimeric form. Utilization of this exogenous enzyme 
allowed the cleavage of the sterically congested trimethyl lock to release the rhodamine. We considered 
this caged rhodamine example and thought we could apply a similar principle to provide us with a 
rhodamine 110 pro-dye.   
 
Figure 4.2. Trimethyl lock scheme using PLE activated rhodamine protecting group43. 
 
Rhodamine 110, protected as a diamide, emits very weak fluorescence but when substituted with 
a peptide sequence specific to proteases, will then emit strong fluorescence when one of those amide 
bonds are cleaved45. The rate of increase in fluorescence can then be detected to find the enzyme’s 
catalytic efficiency (Kcat/KM).  We explored the idea of a protected dye that would demonstrate weak 
fluorescence as a diamide but when in the presence of an enzyme engineered into the cell line, would then 
act as rhodamine 110. This concept had been also utilized to allow the passage of dye into cells as the 
open quinoid form with rhodamine 123, which would then be deesterified by endogenous esterases, and 
act as rhodamine 110 (Figure 4.3, route A) based on reported literature38. Conversely, we would prepare 
diamide protected rhodamines in the closed, spiro-lactone conformation and cells expressing the enzyme 
of interest would release the fluorophore into the fluorescent rhodamine 110 (Figure 4.3, route B). The 
preparation of amide protected rhodamines offered a unique and relatively simple way of caging the dye 
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without too much scaffold modification or a complicated release mechanism. We set forward with initial 
synthesis of PLE selective rhodamine dyes.  
 
 
 
 
 
Figure 4.3. Activated dye from A (Intracellular esterases38) or B (Exogenous hydrolase/amidase)   
 
4.3 Synthesis of PLE-Selective Rhodamine Dyes 
 The salt form of rhodamine 110 is commercially available in large quantities. Formation of the 
diamide protection groups proceeded through either preparation or purchase of the acid chloride derivative  
Scheme 4.2. Synthesizing and evaluating PLE-Pro Dye Rhodamines. R = CH3, CH2CH3, CF3, Phenyl, iPr, tBu. 
 
or the respective anhydride (Table 4.1). Deprotection would then be detected (through change in 
fluorescence) by introduction of dyes to a solution of PLE in assay buffer. Due to the nature of the 
xanthene scaffold, once the rhodamine nitrogens had been acetylated, isolation on silica proceeded 
smoothly. Yields varied from 42-91%, mostly recovering unreacted and/or mono-protected rhodamine 
species. Products were crystalline solids often colorless or faintly orange.  
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Table 4.1. Synthesis of pro-dye rhodamines with ID/VU number, derivative type and yield of reactions. Reaction 
conditions: [a] 2.2 eq acetic or propionic anhydride, 2.1 eq. pyridine and 0.4M DCM.  [b] 2.2 eq RCOCl, where R = iPr, tBu 
or Ar, 5.0 eq. NEt3, and 0.1M DCM. [c] 4.0 eq. (CF3CO)2O, 4.0 eq. NaH, 0.7 M DMF. 
 
 
 
 
 
Compound ID Number R =  Reaction %Yield 
4.1a 0000024HO tBu b 91 
4.1b 0000024HF iPr b 83 
4.1c 0000024HD Ar d 42 
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Table 4.1 cont. Synthesis of pro-dye rhodamines with ID/VU number, derivative type and yield of reactions. Reaction 
conditions: [a] 2.2 eq acetic or propionic anhydride, 2.1 eq. pyridine and 0.4M DCM.  [b] 2.2 eq RCOCl, where R = iPr, tBu 
or Ar, 5.0 eq. NEt3, and 0.1M DCM. [c] 4.0 eq. (CF3CO)2O, 4.0 eq. NaH, 0.7 M DMF. 
Compound ID Number R =  Reaction %Yield 
4.1d VU0806840 CH3 a 89 
4.1e 0000024HQ CH3CH2 a 83 
4.1f VU0806841 CF3 c 76 
 
 Various protected rhodamine derivatives detailed preparation can be found in the experimental 
section (4.9 Experimental). The enzymatic reactivity of the protected rhodamine dyes were then explored 
with commercially available PLE substrate.  
 
4.4 Enzymatic Reactivity of PLE with Prepared Rhodamines 
 We first determined that no deprotection would occur in aqueous solutions before examining the 
stability of the fluorophore in non-transfected cells. All protected rhodamine dyes had no absorbance or 
emission near to the reported values of Rhodamine 110 (ʎmax = 496 nm, ʎem = 517 nm)43. This suggested 
that the fluorophores were locked into the spiro-lactone closed form and non-fluorescent. When mixed 
with a solution of PLE in assay buffer (See Experimental), increase in fluorescence was recorded as the 
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rhodamine dyes were deprotected by the enzyme. We detected the immediate removal of the 
trifluoroacetamide group and learned that this is our most lable pro-dye. We were also pleased to see the 
deprotection of the other available pro-dyes, but noticed that there was a change in rate of fluorescence 
between the different pro-dye protecting groups. Initially, we had been transfecting PLE weekly for our 
assays, but these results encouraged us to generate a PLE expressing cell line and measure change in 
fluorescence. Fortunately, we had previous examples of cell lines expressing PLE through the publications 
of Lavis and coworkers18.  
 
4. 5 Pro-Dye Selectivity With Transient and Stable PLE cell lines 
Transiently Transfected HEK-293 with PLE  
 In situ experiments with PLE demonstrated that the esterase could deprotect the pro-dye as an 
active rhodamine dye. Previous authors had reported expressing PLE in a stable cell line but before 
producing the PLE cell-line, we transiently transfected PLE into readily available HEK-293 and incubated 
with the pro-dyes. The results of these early transfections were encouraging (Figure 4.3) with excellent 
selectivity for dye fluorescence in +PLE transfected cells.  When compared to the standard bis-acetylated 
fluorescein dye (de-esterified by endogenous esterases), we noted an absence of cellular fluorescence at 
the same exposure times. These results were encouraging and led to the development of PLE expressing 
cell line. We transiently transfected HEK-293 cells expressing GIRK1/2 and under selective pressure, 
were able to show fluorescent activity on cells that had been positively transfected with PLE. With these 
results, we then moved to a stable cell line expressing PLE.  
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Figure 4.4. +/-PLE transiently transfected HEK-293 incubated (1h) with pro-dyes [10μM]. PLE expressing cells showed 
fluorescence (0.1ms) when excited at 490nm.   
 
Stable PLE Expressing HEK-293 Cell Line 
Previous publications had provided us with a place to begin, first by subcloning PLE into 
pcDNA3.1/Zeo vector (See Experimental). This work had been performed by Kristopher K. Abney of the 
Weaver laboratory. Production of the PLE expressing cell line has been explained in detail in the 
experimental section. We could quickly determine expression by fluorescence of PLE expressing cells 
when incubated in the pro-dye. This compared to our bisacetylated fluorescein standard, there was an 
absence of fluorescence detected in cells that did not express PLE. Compared to the transiently transfected 
PLE cells, the stable expressing PLE cell line was brighter in fluorescence. To verify our observation of 
variable deprotection rates, we compared the rate of fluorescence using the Panoptic kinetic plate reader.  
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4. 6 Rate of Pro-Dye Deprotection Using Kinetic Plate Reader (Panoptic)  
With the stable PLE producing cell line now accessible, the rate of deprotection with the enzyme in vitro 
can now be determined. First, we desired to repeat our in situ findings with by modifying the assay to our 
needs. Serial dilutions of the pro-dyes would need to be added at a zero time point to generate a best fit 
(v-1/[S]-1 and Km) of the rate of fluorescence with the cells. Panoptic, a kinetic plate reader used for assay 
screening was utilized. Cells expressing PLE were plated and pro-dyes were added in three-fold serial 
dilutions, starting with [40μM] and change in fluorescence was observed (Figure 4.5).  
 
 
Figure 4.5. +PLE stable cell line generated by K. Abney (Weaver). Raw activity data: Rate of fluorescence detected by 
kinetic plate reader on HEK-293 +PLE when exposed to pro-dye serial dilutions. Fluorescence (+) indicated by white and 
absence of fluorescence as black. Pro-Dye G was developed based on previously reported methods46.  
 
We were able to record the change in fluorescence based on concentration of our dyes when exposed to 
cells expressing PLE. As expected, the deprotection of trifluoromethyl acetamide was our most labile 
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protecting group and rapidly fluoresced upon addition to the PLE expressing cells.   We were interested 
to see if the rate of deprotection with PLE in situ was comparable to diffusion and deprotection inside of 
our PLE expressing cell line. First, we wanted to verify if there would be a difference between diffusion 
of the dye into the cells and rate of deprotection. This suggested that the possible difference in derivative 
deprotection was substrate/enzyme related and not permeability into the cell. The relative rates of 
deprotection were generated based on concentration response series. We did not generally detect a major 
increase or decrease in time of onset onto fluorescence, in fact, we were pleased to see the similar trends 
of high activity with the trifluoroacetamide when compared in situ PLE activity and cells expressing PLE. 
When the slope (concentration/activity) was plotted over time, we uncovered comparable trends in 
activity of the enzyme alone or cells expressing PLE (Table 4.2).   
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Table 4.2. Km of Pro-dye rhodamine derivatives rate of deprotection by PLE reported as [dye] of PLE expressing cells 
compared to in situ.   
 
Compound  R Group Cell (M) In situ (M) 
4.1d CH3 1.90 X10
-4 1.63 X10-4 
4.1e CH2CH3 1.85 X10
-4 1.65 X10-4 
4.1b iPr 2.17 X10-4 2.40 X10-4 
4.1a tBu 1.81 X10-4 2.30 X10-4 
4.1f CF3 1.92 X10
-4 2.67 X10-4 
4.1c Aryl 3.87 X10-4 4.76 X10-5 
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Figure 4.6. Histogram representing activity (total fluorescence normalized to rhodamine control) of PLE substrate 
rhodamines in +/-PLE cells. 100% equals total fluorescent activity of the control standard. The –CF3 protected acetamide 
rhodamines were the most active compared to aryl or methyl, but surpassed by “ethyl” protected acetamide (propionamide).  
 
Rates of deprotection of pro-dyes varied based on amide groups (Figure 4.5). The strongly electron 
withdrawing group trifluoromethyl acetamide had the highest rate of fluorescence increase compared to 
the other pro-dyes, suggesting that this group was incredibly liable for rhodamine deprotection. Next, the 
propionamide seemed to offer more of the properties we were looking for, both being reasonable liable 
but offering some chemical stability. We decided to move forward with the propionamide “ethyl” 
protected rhodamines as our PLE pro-dye for use in selectivity assays.  
4. 7 Applying Pro-Dyes in Selectivity Assays 
We originally desired to have a selective dye, that only under the correct conditions, would 
fluoresce and give us an advantage by reducing background noise typically experienced by other 
fluorescent dyes. Our first thought was to use the pro-dye/enzyme pair as a screening tool, first in cells 
that selectively expressed our enzyme of interest, and then primary cultures of tissue, which would then 
Total Fluorescent Activity  
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repress any tissue that did not contain the correct factors. Unfortunately, when screening for possible aryl-
amide substrates of PLE (NIH Clinical Collection I and II ~760 compounds), we identified a number of 
“inhibitors” of PLE in the assay (~25% showed inhibitor activity). This would lead to false positives, or 
ineffective dye activity if we were to continue use of this pro-dye/enzyme pair in experimental compound 
conditions. A variety of these test compounds had a scaffold that contained an aryl amide. Due to these 
uncertainties, we would need to use the pro-dye with substrates that would not inhibit PLE.   
  
 
Figure 4.7. (Left) VU0523039 and (right) VU0496934 positive hits for PLE “inhibition”. 
 
Rhodamine Pro-Dyes to Study Mitochondria 
 Early studies of mitochondria have showed that they play an important role in the generation of 
energy essential for a cell. It is no surprise that morphology of a mitochondria influenced by differing 
states of a cell, including cell cycle and pathological states. Much work has been done in the area of dye 
staining of mitochondria in living cells, commonly used in fluorescence microscopy, flow cytometry and 
spectroscopy.  Rhodamine 123, the methyl ester version of rhodamine 110 (Figure 4.8) with the locked 
“open quinoid” form, is specifically taken up by mitochondria (as a substrate or passively diffused38) with 
little to no staining of the nucleus and presents low cytotoxic effects47.  
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Figure 4.8. Rhodamine 123 and 110 cellular dyes 
 
Rhodamine 123 is metabolized into rhodamine 110 by intracellular esterases38 which has different 
fluorogenic properties and glucuronidated48 as a substrate for MRP249. Based on earlier assumptions that 
rhodamine 123 is converted into rhodamine 110, we expected that our pro-dye rhodamines would also be 
taken up by the mitochondria in a similar manner.  
 
Rhodamine Pro-Dyes Cellular Staining  
Based on previous work exploring the metabolism of rhodamine 123 to rhodamine 110, we 
expected a similar route with the pro-dye as a PLE substrate. Due to this assumption, we anticipated that 
rhodamine 110 was the active form of the dye that stained mitochondria and expected this to occur with 
the pro-dye substrates. Inversely, this was not the case as shown in Figure 4.8. In +PLE expressing cells, 
we compared our “ethyl” pro-dye, rhodamine 123 and rhodamine 110. Rhodamine 123 performed as 
expected but with a relative lower fluorescent signal than rhodamine 110 or the pro-dye. Cytosolic 
staining was observed with rhodamine 110 and the pro-dye. We reasoned this could be due to the “over-
loading” of the cells with dye and visually blocking any potential mitochondrial signal. Mechanistically, 
we expected that rhodamine 123 would be converted into rhodamine 110, but there is a disconnection 
between when and where this occurs. Additional evidence suggests at least one metabolic pathways for 
rhodamine 123 (as it has been used for tumor identification in murine studies48), a glucuronidated 
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metabolite that returns to the parent rhodamine 123 upon incubation with β-glucronidase. These results 
were initially disappointing but suggested an additional line of thought. The mechanism for rhodamine 
123 to rhodamine 110 had been well established but we could not conclude that was the case with the 
conversion of our pro-dyes into rhodamine 110. We were approaching the mechanism of desterification 
in a linear way: rhodamine 123 is deesterified into rhodamine 110. It is not entirely impossible that 
rhodamine 123 metabolites are formed. In addition to metabolites, we had not even begun to address how 
a dianion fluorophore will accumulate in different regions of the cell than a zwitterion or even a neutral 
fluorophore. The most basic pH assumption is that positively charged rhodamine species accumulate in 
the mitochondria due to the negative membrane potential. I offer some approaches to answer these 
questions in Chapter 5 – though superficial as a mitochondrial membrane sensor, we can begin to explore 
what may actually be happening to rhodamine 123 and our pro-dyes.  
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Figure 4.9. Cellular staining of HEK-293 cells expressing PLE. All dyes incubated at [10μM] for 30 minutes. Images 
obtained at 350 or 490nm excitation at respective exposure times. (Top Left)  Hoechst nuclear stain 0.01ms (Top Right) ”Ethyl” 
pro-dye  selectively fluoresces with +PLE expressing cells. Note cytosolic accumulation 0.01ms (Bottom Left) Rhodamine 
123 mitochondrial dye 0.2ms. (Bottom Right) Rhodamine 110 accumulates in the cytosol similar to the activated pro-dye  
0.01ms.  
 
 
4.8 Conclusion and Future Directions 
 In this chapter, we successfully demonstrated pro-dye/enzyme selectivity with PLE expressing 
cells with a variety of pro-dye rhodamine derivatives. Additionally, we were able to identify our best pro-
dye substrates using PanOptic kinetic plate reader assay by reporting the increase in fluorescence over 
time with varying concentrations (R= CF3, CH2CH3). Previously reported by Lavis, caged compounds 
have the ability to be selectively activated but this work was the first demonstration of a variety of similar 
Hoechst  +PLE Pro-Dye 
Rhod 123 Rhod 110 
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substrates that had been evaluated for their enzymatic affinity and selectively activated. The utility of 
producing a number of similar dyes and assaying with an exogenous enzyme offers a high potential for 
future use in cellular assays. We suggested the use of the dyes as mitochondrial membrane potential 
sensors and still potentially could be used for that purpose. Additional important questions have formed 
based on cellular staining results, perhaps examining our understanding of the endogenous conversion of 
rhodamine 123 to rhodamine 110, which now will be explored in Chapter 5.  
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4.9 Experimental  
General Experimental 
All glassware used for reactions was flame dried under vacuum. All reagents and solvents were 
commercial grade and purified prior to use when necessary. All reactions were performed under 
argon atmosphere unless otherwise stated. Diethyl ether (Et2O) and dichloromethane (CH2Cl2) 
were dried by passage through a column of activated alumina using an MBraun MB-SPS dry 
solvent system. Tetrahydrofuran (THF) was distilled from sodium with benzophenone as indicator 
prior to use. 
Reactions were monitored by analytical thin-layer chromatography performed on Analtech silica 
gel GF 250 micron plates. The plates were visualized with UV light (254 nm) and either potassium 
permanganate, ceric ammonium molybdate, or p-anisaldehyde followed by charring on a hot-plate. 
Flash chromatography utilized 230-400 mesh silica gel (SiO2) from Sorbent Technologies or Silica 
RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system. Solvents 
for extraction, washing and chromatography were HPLC grade. 
Nuclear magnetic resonance (NMR) spectra were acquired on either a 300 MHz Bruker DPX-300 
FT-NMR, a 400 MHz Bruker AV-400 FT-NMR, or 500 MHz Bruker DRX-500 FT-NMR 
Spectrometer at ambient temperature. 1H and 13C NMR data are reported as values relative to 
CDCl3. 
1H chemical shifts are reported in δ values in ppm. Data are reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
integration, coupling constant (Hz). 13C chemical shifts are reported in δ values in ppm. Low 
resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer with 
electrospray ionization. High resolution mass spectra were recorded on a Waters Q-TOF API-US. 
Analytical HPLC was performed on an Agilent 1200 series with UV detection at 214 nm and 254 
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nm along with ELSD detection. Preparative HPLC was conducted on a Gilson 215 Liquid Handler 
HPLC system using Gemini-NX 50 x 20 mm column. Cellular imaging was done on a Zeiss 
Axiovert 200 microscope using 20X0.8 objective to collect fluorescence data.  
 
Synthesis of Rhodamine Pro-dye PLE substrates 
 
 
 
 
 
 
N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)diacetamide. To a solution of 
Rhodamine 110 chloride (0.1g, 0.27 mmol) in dichloromethane (0.4M) were added acetic 
anhydride (0.06 mL, 0.6 mmol) and pyridine (0.1mL, 0.57 mmol). The mixture was stirred until 
judged complete by TLC (1:1 hex/EtoAc). When complete, reaction was washed with sodium 
carbonate (20 mL) and extracted with EtOAc (3X50mL). Organic layer was combined, dried over 
MgSO4, and concentrated in vacuo to yield a crude orange solid. The residue was purified by 
column chromatography with hexane/ethyl acetate (4:1 to 1:1)to yield 89 mg (90%) of N,N'-(3-
oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)diacetamide 4.1d  as a white solid.  1H NMR 
(400 MHz, CDCl3): δ7.92 (d, J = 7.6 Hz 1H), 7.79 (s, 2H), 7.57 (m, 2H), 7.37 (s, 2H), 7.07 (m, 
3H), 6.61 (d, J = 8.6 Hz, 2H), 2.13 (s, 6H). LCMS calculated for C24H18N2O5 (M+H)
+ m/z: 414.4, 
Measured 415.0 m/z. 
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N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)dipropionamide.  To a solution 
of Rhodamine 110 chloride (0.05g, 0.14 mmol) in dichloromethane (3.0mL, 0.4M) were added 
propionic anhydride (0.04 mL, 0.30 mmol) and pyridine (0.05mL, 0.286 mmol). The mixture was 
stirred until judged complete by TLC (1:1 hex/EtoAc). When complete, reaction was washed with 
sodium carbonate (20 mL) and extracted with EtOAc (3X50mL). Organic layer was combined, 
dried over MgSO4, and concentrated in vacuo to yield a crude orange solid. The residue was 
purified by column chromatography with hexane/ethyl acetate (1:1 to flush with EtOAc) to yield 
50 mg (80%) of N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)dipropionamide 
4.1e as a white solid.  1H NMR (400 MHz, MeOD): δ8.04 (d, J = 7.6 Hz, 1H), 7.81-7.71 (m, 4H), 
7.23-7.16 (m, 3H), 6.72 (d, J = 8.8 Hz 2H), 2.42 (q, J = 7.6 Hz, 4H), 1.22 (t, J = 7.0 Hz, 6H). 13C 
NMR (400 MHz, MeOD): δ8.53, 29.5, 82.8, 106.9, 113.6, 115.1, 123.6, 124.4, 126.1, 127.8, 129.8, 
135.2, 141.0, 151.5, 152.9, 169.8, 174.1. LCMS calculated for C26H22N2O5 (M+H)
+ m/z: 442.4, 
Measured 443.0 m/z. 
 
 
N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)bis(2,2,2-trifluoroacetamide) 
– To a solution of Rhodamine 110(100 mg, 0.3 mmol) in 5.0 mL of DMF added slowly NaH (60%, 
50 mg, 1.2 mmol).  This was then allowed to stir at R.T. for 1 h.  At this time triflouroacetic 
anhydride (170μL , 1.2 mmol) was added.  This was then allowed to stir for 16 h.  At this time 
AcOH (3 drops) was added and the organics were then concentrated.  The crude product was then 
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purified by column chromatography with a gradient of 20-100% Hexane:EtOAc to afford 122 mg 
(76%) of the desired product 4.1f. 1H NMR (CDCl3) δ8.08 (d, J = 7.5 Hz, 1H), 7.97 (bs, 2H), 7.79 
(d, J = 2.0 Hz, 2H), 7.74-7.66 (m, 2H), 7.19 (d, J = 2.0 Hz, 1H), 7.17-7.15 (m, 2H), 6.89 (d, J = 
8.6 Hz, 2H); 19F NMR (CDCl3) δ-75.6; LCMS calculated for C24H12F6N2O5 (M+H)+ 523.1 m/z: 
Measured 522.9 m/z. This compound had been graciously synthesized by Dr. Ian Romaine.  
 
 
 
 
 
 
N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)dibenzamide.  To a solution of 
Rhodamine 110 chloride (0.05g, 0.14 mmol) in dichloromethane (0.4M) and triethylamine (0.1mL, 
0.682 mmol)were added benzoyl chloride dropwise (30μL, 0.30 mmol). The mixture was stirred 
until judged complete by TLC (1:1 hex/EtoAc). When complete, reaction was concentrated in 
vacuo to yield a crude orange solid. The residue was purified by column chromatography with 
hexane/ethyl acetate (1:1 to flush with EtOAc) to yield 30 mg (42%) of N,N'-(3-oxo-3H-
spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)dibenzamide 4.1c as a white solid.  1H NMR (400 
MHz, CDCl3): δ8.75 (s, 2H), 8.08 (d, J = 7.4 Hz, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.80 (d, J = 7.5 Hz, 
4H), 7.66-7.55 (m, 2H), 7.47-7.41 (m, 3H), 7.33-7.30 (m, 2H), 7.25-7.21 (m, 2H), 7.12 (d, J =  7.6 
Hz, 1H), 6.61 (d, J =  8.6 Hz, 2H). 13C NMR (400 MHz, CDCl3): δ83.1, 108.4, 114.0, 116.2, 124.1, 
124.9, 126.0, 127.2, 128.1, 128.3, 128.5, 129.8, 130.0, 131.9, 133.5, 134.1, 135.4, 140.2, 151.4, 
152.9, 166.3, 169.9. LCMS calculated for C34H22N2O5 (M+H)
+ m/z: 538.6, Measured 539.0 m/z. 
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N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)bis(2,2-
dimethylpropanamide)- To a solution of Rhodamine 110 chloride (0.05g, 0.14 mmol) in 
dichloromethane (1.36mL, 0.4M) and triethylamine (0.1mL, 0.682 mmol) were added 
trimethylacetyl chloride dropwise (40μL, 0.30 mmol). The mixture was stirred until judged 
complete by TLC (1:1 hex/EtoAc). When complete, reaction was concentrated in vacuo to yield a 
crude orange solid. The residue was purified by column chromatography with hexane/ethyl acetate 
(1:1 to flush with EtOAc) to yield 55 mg (91%) of N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-
xanthene]-3',6'-diyl)bis(2,2-dimethylpropanamide) 4.1a as a white solid.  1H NMR (400 MHz, 
MeOD): δ8.03 (d, J = 7.6 Hz, 1H), 7.79-7.69 (m, 4H), 7.26-7.19 (m, 3H), 6.71 (d, J = 8.4 Hz, 2H), 
1.31 (s, 18H). 13C NMR (400 MHz, MeOD): δ26.2, 39.3, 83.2, 108.2, 113.9, 116.3, 123.6, 124.4, 
126.2, 127.6, 129.8, 135.9, 140.9, 151.4, 153.0, 170.2, 178.6. LCMS calculated for C34H22N2O5 
(M+H)+ m/z: 498.5, Measured 499.0 m/z. 
 
N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)bis(2-methylpropanamide)– 
To a solution of Rhodamine 110 chloride (0.05g, 0.14 mmol) in dichloromethane (3.0mL, 0.1M) 
and triethylamine (0.1mL, 0.682 mmol) were added isobutyryl chloride dropwise (10μL, 0.82 
mmol). The mixture was stirred until judged complete by TLC (1:1 hex/EtoAc). When complete, 
reaction was concentrated in vacuo to yield a crude orange solid. The residue was purified by 
column chromatography with hexane/ethyl acetate (1:1 to flush with EtOAc) to yield 51 mg (83%) 
of N,N'-(3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl)bis(2-methylpropanamide) 4.1b 
as a white solid.  1H NMR (400 MHz, MeOD) δ8.03(d, J = 7.4 Hz 1H), 7.81-7.70 (m, 4H), 7.22-
7.17 (m, 3H), 6.71 (d, J = 8.6 Hz 2H), 2.65 (q, J = 6.8 Hz  2H), 1.21 (d, J = 6.8 Hz, 12H); 13C NMR 
(400 MHz, MeOD) δ18.3, 35.6, 82.8, 107.1, 113.6, 115.3, 123.6, 124.4, 126.2, 127.8, 129.8, 135.3, 
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141.1, 151.5, 152.9, 169.8, 177.4; LCMS calculated for C23H18N2O4 (M+H)
+ 470.5 m/z: Measured 
471.0 m/z 
 
Cellular Experimental 
Cell Line Formation  
pCAG-PLE-IRES-mCherry (addgene, Lavis L) vector was taken and amplified using chemically 
competent DH5α E.coli cells. The PLE-IRES-mCherry DNA was purified using QIAprep Spin 
Miniprep kit (Qiagen) and quanitifed on a NanoDrop ND-1000 spectrophotometer (Thermo 
Fisher).  Using the protocols described by New England Biosciences, restriction endonuclease 
enzyme digestion used Not1-HF and Xho1 to cleave PLE-IRES-mCherry insert from the pCAG 
backbone. The digestion was purified by regular agarose gel electrophoresis using the QIAquick 
Gel Extraction kit (Qiagen).  In order to confer selective pressure, the PLE-IRES-mCherry insert 
was cloned into pcDNA3.1/Zeo vector. The insert and vector were combined using T4 DNA ligase 
(Thermo Fisher). The pcDNA3.1/Zeo PLE-IRES-mCherry vector was introduced to HEK293 
(ATCC) cells by means of cationic lipids (FuGENE HD Promega), and selected for by using 
Zeocin.  Cells were maintained in cell culture medium, alpha MEM ( 10% vol/vol FBS (Thermo-
Fisher) and 1% GlutaGro (Corning)) in a cell culture incubator at 37oC with 5% CO2. 
 
Kinetic Dye Assays 
 For kinetic dye assays, we used PLE-IRES-mCherry expressing HEK293 cells (ATCC), referred 
to as PLE cells. PLE cells were dislodged from T-175 tissue culture flasks using TrypLE Express 
(Life Sciences, Carlsbad, CA), then transferred into a 50mL conical tube, and centrifuged at 500g 
for 2 min. The supernatant solution was aspirated and resuspended at a concentration of 
86 
 
~1000cell/µL in alpha MEM ( 10% vol/vol FBS (Thermo-Fisher) and 1% GlutaGro (Corning)) . 
Twenty µL of the cell suspension were plated into amine coated, clear-bottom, and black walled 
384 well plate (cat# 354719, BD, Franklin Lakes, NJ) by an electronic multichannel pipette. Plates 
were then cultured overnight at 5% CO2 in a cell culture incubator at 37oC. Following overnight 
incubation, cell culture medium was removed and replaced with dye-loading assay buffer (Hank’s 
Balanced salt solution, 20mM HEPES). The dyes: R= CH3, CH2CH3, iPr, tBu, CF3, and Aryl 
were added into assay buffer with a final concentration of 0.01% DMSO. The plates where then 
loaded into a WaveFront Panoptic (Nashville, TN). The data were acquired at 1Hz (excitation 
470±  20nm and 540 ± 30nm), then 20uL/well of the aforementioned dyes were added and 
incubated for 15 minutes.  Fluorescence was measured following addition of dyes into cell wells 
and data collection continued for 15 total minutes. Data were analyzed using Microsoft Office as 
described in Kaufmann et al.9 and slopes were collected. XLfit (IDBS, Surrey, UK) was utilized 
to create fits to a 4 parameter logistic equation. Test Dyes compounds were solubilized in DMSO 
to 50µM. A 7-point 3 fold serial dilution was achieved using an electronic pipette. All data 
represent at least 3 independent experiments per compound concentration and all DMSO 
concentration is 0.01% or less. Experiments involving FCCP, the cells were incubated with R= 
CH2CH3 dye for 30 minutes. FCCP was then added to PLE cells and control cells in varying 
concentrations.   
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APPENDIX 
NMRS FOR CHAPTER 4 
 
 
 
Figure 4.9. 1H-NMR spectrum (400 MHz, MeOD) and 13C-NMR spectrum (400 MHz, MeOD) of 4.1e. 
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Figure 4.10. 1H-NMR spectrum (400 MHz, MeOD) and 13C-NMR spectrum (400 MHz, MeOD) of 4.1a.  
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Figure 4.11. 1H-NMR spectrum (400 MHz, MeOD) and 13C-NMR spectrum (400 MHz, MeOD) of 4.1b. 
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Figure 4.12. 1H-NMR spectrum (400 MHz, DMSO) and 13C-NMR spectrum (400 MHz, DMSO) of 4.1c. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS  
5.1 Introduction 
 This chapter serves as a place to expand upon ideas or questions we may have about the 
experiments previously described. In chapters 2 and 3, GIRK channels were heavily explored with 
an armory of molecular probe scaffolds. This opened up opportunities for other researchers to 
explore GIRK channels with their own probe design (Trauner, LOGOs) and propose some novel 
ideas for the exploration of binding pocket locations. Chapter 4 diverged from the GIRK probe 
theme but instead focused on fluorophore development for use in GIRK assays. Exploring 
selectively activated fluorophores provided a powerful platform for future discoveries with GIRK 
assays. Some questions have yet to be answers concerning the future use of pro-dye/enzyme pair 
but the following suggestions may lead a future researcher to the currently unsolved.  
 
5.2 Chapter 2 Conclusions and Future Directions of Discovery and SAR of a Novel Series of 
GIRK1/2 and GIRK1/4 Activators: “Sulfonamide Series” 
 The results of the work in chapter 2 helped to identify a novel scaffold that was still active 
on GIRK channels. Very recently published by the Trauner and Weaver50, light operated GIRK 
channel openers (LOGOs) were developed based on the sulfonamide scaffolds. Azo-benzenes are 
known to photo-switch or isomerize to a cis or trans geometry in the presence of light. The probe 
in figure 5.1 was synthesized and used to selectively activate GIRK1 containing GIRK channels 
at 440nm as the trans-isomer.  
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Figure 5.1. LOGO5 was found to selectively activate GIRK channels in the presence of 440nm.   
 
Interestingly, LOGOs developed with the ML297 urea scaffold (not shown) were active as the 
trans-isomer but upon photolysis to the cis-isomer (360nm), only a small decrease of GIRK current 
was noted. Further attention then went to the development using the amide based scaffold, which 
then worked as an excellent photo-switch. Application of these probes were verified using 
electrophysiology and then incubated with zebrafish larvae. They compared the photolysis 
LOGO5 probe with results from ML297 and found comparable changes in swimming behavior.  
 
 The previous study was an example of how the results of these probes can be translated 
into higher order organisms or even primary cultures to investigate GIRK activation. With the 
LOGOs investigation, the ML297 like urea probe was found to activate GIRK channels regardless 
to the cis or trans isomer. This approaches the question of the binding pocket location on the GIRK 
channel and how residues associated with this region play a steric role. We had previously learned 
from Wydeven and coworkers51 about the importance of two residues that seemed necessary for 
ML297 activity. Accessing GIRK mutants with point mutations and the power of LOGOs could 
help us understand the binding region if activity increases or decreases upon photolysis. Also, it 
was interesting to note how much the GIRK channels tolerated the extension of the aromatic 
system. Previously, we had discussed how sensitive the pyrazole C3 substituent was to selectivity 
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and GIRK1 activity. The LOGOs probes extend out with the azo-benzene past what we had 
originally assumed the channel binding region would “accommodate”.  
 
 
Figure 5.2. Implementing more sulfonamide probes based off of LOGOs results.   
 
 Additionally, ML297 suffers from is its insolubility due to the urea scaffold. Modification 
to an amide scaffold with varying functional groups may provide improved solvation. Exploring 
around the sulfonamide may provide some useful SAR information, possibly leading to a better 
affinity probe for use in the LOGOs studies. One drawback highlighted was the inability to produce 
a red-shifted photo-switching probe. Longer wavelength probes first move the excitation 
wavelength away from cellular damaging UV light and offer deeper tissue penetration, perhaps 
translating these studies into primary cultures or in vivo murine models with fiber optics.  
 
5.3 Chapter 3 Conclusions and Future Directions of Discovery of a Stereo-Specific 
Modulation of GIRK1/2 and GIRK1/4 Channels: Synthesis and Evaluation of 2-
Methylcyclopropyl Enantiomers 
 The findings in Chapter 3 with GIRK1 selectivity based on enantiomeric preference offers 
a more subtle look at how GIRK channels are activated (or inhibited). ML297 was 6-10 fold more 
active on GIRK1/2 channels but was still activate on GIRK1/4. Finding that the 2-methyl 
cyclopropyl probes were active on GIRK1/2 but inactive or inhibitory on GIRK1/4 suggests a 
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delicate selectivity for interaction with the channel. Adventitious in selectivity but not activity, the 
probes did not have the highest efficacy nor potency as ML297 (EC50 = 0.160 μM) or derivatives, 
leading them to be a medocore candidate for anything other than selectivity studies. The 2-methyl 
cyclopropyl route to pure (1R, 2R) or (1S, 2S) enantiomers has been established, however, not 
trivial, may be repeated to generate the pyrazole coupling piece. This built in flexibly in the last 
step allows the potential to generate another small library of compounds.  
Due to the convergent nature of building ureas, exploring areas of the molecule while 
holding the other constant is an excellent way to probe structure and activity relationships. 
Pyrazoles with a varying alkyl group in the C3 position lead to Wen and co-worker35’s molecular 
switch of an isopropyl inhibitor to a cyclopropyl activator, but the original ML297 screen held the 
methyl pyrazole constant. Holding the 3,4-difluorophenyl moiety constant to better explore the 
steric relationship with the pyrazole, we can then investigate the relevance of the bulk of that group 
Also, the benzyl derivative of ML297 demonstrated potency on both GIRK1/2 and GIRK1/4 with 
high efficacy relative to ML297. A benzylic methylene is not planar and has free rotation to 
position the phenyl in a more favorable conformation in the GIRK binding pocket. Locking in a 
conformer with a phenylethyl enantiomer would set the direction of the phenyl and tease out any 
preference. Additionally, we can solidify this enantiomer preference by introducing the methyl 
cyclopropyl enantiomer to the pyrazole by looking to increase potency on GIRK channel 
preference. We would start with the GIRK enantiomer preference probe, (1S,2S) 2- methyl 
cyclopropyl. 
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Figure 5.3. Examining enantiomer preference with (1S,2S) 2-methyl cycloproyl probes and R or S phenylethyl 
pyrazole modification.   
 Considering how to go about synthesizing phenylethyl pyrazole enantiomers, we thought 
about how to construct the hydrazine needed for the condensation on the desired β-keto nitrile. Sn2 
on a benzyl halide to a hydrazine potentially would cause enantiopurity issues so we thought to 
use a substrate with the stereocenter already in place. A solution to this problem are oxaziridines; 
an oxidant with two electronegative atoms, oxygen and nitrogen in a strained three member ring. 
Williamson and coworkers52 recently reported on the usefulness of these oxidants through a variety 
of transformations, including electrophilic transfer of the nitrogen atom. Amination of a nitrogen 
to form the desired hydrazine was pioneered by Andreae and Schmitz53, offering a way to form 
peptide hydrazines with no racemization from the chiral amino acid. Vidal and coworkers prepared 
N-Moc and N-Boc protected hydrazines54, starting with 4-cyanobenzaldeyde reacted with aza-
Wittig and oxidized to the oxaziridine using buffered Oxone (potassium peroxymonosulfate). The 
Boc-protected imine can also be isolated through a base catalyzed elimination of a sulfonyl from 
the benzyl carbamate55, and then oxidized using similar conditions. With the pyrazole 
stereoisomers in hand, we then may couple with an isocyanate to produce the urea small molecule 
probe. Once assayed, we then can determine our future directions with molecular modeling using 
these data.  
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5.4 Chapter 4 Conclusions and Future Directions of Selective Rhodamine Pro-dye/Enzyme 
Releasing Pair: Mitochondrion Membrane Potential Sensors 
 In Chapter 4, we had evaluated a series of rhodamine pro-dyes with an exogenously 
expressed enzyme PLE in cell lines. We had demonstrated exquisite activation and selectivity with 
the cells expressing PLE verses the cells that were not. This led to the potential of using the cell 
line expressing our enzyme as mitochondrial membrane potential sensors. Initial experiments were 
conducted on its use as a membrane potential sensor but until following up with cellular staining 
(Figure 4.9), we uncovered that our expectations of our pro-dye as a mitochondrial dye were not 
as anticipated. In fact, when compared to rhodamine 123 (a known mitochondrial dye), rhodamine 
110 failed to perform similarly, despite the known conversion of rhodamine 123 to rhodamine 110 
by endogenous enzymes. Seeing as we had pro-dyes that were protected and converted to 
rhodamine 110, this left a very large question:  What was different about rhodamine 123 that 
allowed it to preferentially stain mitochondria despite its known metabolite rhodamine 110 being 
reported consistently? Thinking about this problem, especially considering what we have learned 
about our pro-dyes, we propose this substrate to evaluate in Figure 5.4.  
 
 
Figure 5.4. (Left) Proposed Rhodamine 123 based pro-dye off of (Right) Pro-dye 4.1e.  
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Accessing the pro-dye derived from rhodamine 123 would require treatment in basic conditions56 
with either propionic acid or propionyl chloride. This pro-dye should then validate if mitochondrial 
staining occurs due to the methyl ester moiety. Unfortunately, we expect this pro-dye to be 
fluorescent due to the open conformation but we are unsure of the exact quantum yield with the 
acetylated nitrogens.  In another approach, we could learn more about the metabolic profile of 
rhodamine 123 and our pro-dyes, and compare lysates of cells that have been treated with the pro-
dye and those without. Similar to the glucuronidation studies, we could determine the metabolites 
present using mass spectrometry and comparing to the known compounds.  
 
5.5 Concluding Remarks  
 The utility of molecular tools for the investigation of complex biological system is only 
limited by our imagination. We have come to some solid conclusions on what may be happening 
with GIRK channels but many questions remain unanswered or not even conceived yet. The impact 
of these tools hopefully will begin to unravel the complexity of GIRK channels and may even one 
day offer us a solution to the host of disorders we currently do not have the cure for.   
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